

David F Penson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3631174/publications.pdf>

Version: 2024-02-01

650
papers

28,927
citations

8180

76
h-index

5987

160
g-index

685
all docs

685
docs citations

685
times ranked

25140
citing authors

#	ARTICLE	IF	CITATIONS
1	Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer. New England Journal of Medicine, 2010, 363, 411-422.	27.0	4,724
2	Update on AUA Guideline on the Management of Benign Prostatic Hyperplasia. Journal of Urology, 2011, 185, 1793-1803.	0.4	946
3	Early Detection of Prostate Cancer: AUA Guideline. Journal of Urology, 2013, 190, 419-426.	0.4	945
4	Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 479-505.	4.9	943
5	Long-Term Functional Outcomes after Treatment for Localized Prostate Cancer. New England Journal of Medicine, 2013, 368, 436-445.	27.0	803
6	Overdiagnosis Due to Prostate-Specific Antigen Screening: Lessons From U.S. Prostate Cancer Incidence Trends. Journal of the National Cancer Institute, 2002, 94, 981-990.	6.3	786
7	Epidemiology and cost of ventral hernia repair: making the case for hernia research. Hernia: the Journal of Hernias and Abdominal Wall Surgery, 2012, 16, 179-183.	2.0	723
8	Overdiagnosis and Overtreatment of Prostate Cancer. European Urology, 2014, 65, 1046-1055.	1.9	709
9	Five-Year Outcomes After Prostatectomy or Radiotherapy for Prostate Cancer: The Prostate Cancer Outcomes Study. Journal of the National Cancer Institute, 2004, 96, 1358-1367.	6.3	577
10	Adverse Effects of Androgen Deprivation Therapy and Strategies to Mitigate Them. European Urology, 2015, 67, 825-836.	1.9	561
11	Nationwide Trends in Mastectomy for Early-Stage Breast Cancer. JAMA Surgery, 2015, 150, 9.	4.3	545
12	Prostate Cancer, Version 1.2016. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 19-30.	4.9	544
13	5-YEAR URINARY AND SEXUAL OUTCOMES AFTER RADICAL PROSTATECTOMY: RESULTS FROM THE PROSTATE CANCER OUTCOMES STUDY. Journal of Urology, 2005, 173, 1701-1705.	0.4	426
14	Prostate Cancer and the Will Rogers Phenomenon. Journal of the National Cancer Institute, 2005, 97, 1248-1253.	6.3	369
15	Quantifying the role of PSA screening in the US prostate cancer mortality decline. Cancer Causes and Control, 2008, 19, 175-181.	1.8	345
16	NCCN Guidelines Insights: Prostate Cancer, Version 1.2021. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 134-143.	4.9	299
17	Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial. Journal of Clinical Oncology, 2016, 34, 2098-2106.	1.6	264
18	Association Between Radiation Therapy, Surgery, or Observation for Localized Prostate Cancer and Patient-Reported Outcomes After 3 Years. JAMA - Journal of the American Medical Association, 2017, 317, 1126.	7.4	261

#	ARTICLE	IF	CITATIONS
19	Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer. <i>New England Journal of Medicine</i> , 2020, 382, 2197-2206.	27.0	253
20	ICUD-EAU International Consultation on Bladder Cancer 2012: Urinary Diversion. <i>European Urology</i> , 2013, 63, 67-80.	1.9	238
21	Why do men choose one treatment over another?. <i>Cancer</i> , 2006, 106, 1865-1874.	4.1	234
22	HEALTH RELATED QUALITY OF LIFE AFTER RADICAL CYSTECTOMY AND URINARY DIVERSION FOR BLADDER CANCER: A SYSTEMATIC REVIEW AND CRITICAL ANALYSIS OF THE LITERATURE. <i>Journal of Urology</i> , 2005, 173, 1318-1322.	0.4	215
23	Castration-Resistant Prostate Cancer: AUA Guideline. <i>Journal of Urology</i> , 2013, 190, 429-438.	0.4	206
24	Do Impotent Men With Diabetes Have More Severe Erectile Dysfunction and Worse Quality of Life Than the General Population of Impotent Patients?: Results from the Exploratory Comprehensive Evaluation of Erectile Dysfunction (ExCEED) database. <i>Diabetes Care</i> , 2003, 26, 1093-1099.	8.6	199
25	Race/Ethnicity, Obesity, Health Related Behaviors and the Risk of Symptomatic Benign Prostatic Hyperplasia: Results From the Prostate Cancer Prevention Trial. <i>Journal of Urology</i> , 2007, 177, 1395-1400.	0.4	196
26	General Quality of Life 2 Years Following Treatment for Prostate Cancer: What Influences Outcomes? Results From the Prostate Cancer Outcomes Study. <i>Journal of Clinical Oncology</i> , 2003, 21, 1147-1154.	1.6	173
27	LAPAROSCOPIC PARTIAL NEPHRECTOMY AND PROSTATECTOMY: WEIGHING THE COSTS AND THE BENEFITS. <i>Journal of Urology</i> , 2004, 172, 6-7.	0.4	173
28	Optimization of Initial Prostate Biopsy in Clinical Practice: Sampling, Labeling and Specimen Processing. <i>Journal of Urology</i> , 2013, 189, 2039-2046.	0.4	173
29	Patient-Reported Outcomes Through 5 Years for Active Surveillance, Surgery, Brachytherapy, or External Beam Radiation With or Without Androgen Deprivation Therapy for Localized Prostate Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 149.	7.4	172
30	Dietary Patterns, Supplement Use, and the Risk of Symptomatic Benign Prostatic Hyperplasia: Results from the Prostate Cancer Prevention Trial. <i>American Journal of Epidemiology</i> , 2008, 167, 925-934.	3.4	169
31	Health Related Quality of Life in Men With Prostate Cancer. <i>Journal of Urology</i> , 2003, 169, 1653-1661.	0.4	166
32	Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017. <i>Journal of Clinical Oncology</i> , 2018, 36, 414-424.	1.6	155
33	Effect of Age, Tumor Risk, and Comorbidity on Competing Risks for Survival in a U.S. Population-Based Cohort of Men With Prostate Cancer. <i>Annals of Internal Medicine</i> , 2013, 158, 709.	3.9	147
34	The association between socioeconomic status, health insurance coverage, and quality of life in men with prostate cancer. <i>Journal of Clinical Epidemiology</i> , 2001, 54, 350-358.	5.0	142
35	Quality of Life After Breast Cancer Diagnosis and Survival. <i>Journal of Clinical Oncology</i> , 2011, 29, 406-412.	1.6	137
36	Radical Cystectomy With Extended Lymphadenectomy: Evaluating Separate Package Versus en Bloc Submission for Node Positive Bladder Cancer. <i>Journal of Urology</i> , 2007, 177, 876-882.	0.4	136

#	ARTICLE	IF	CITATIONS
37	Androgen and Pituitary Control of Penile Nitric Oxide Synthase and Erectile Function in the Rat1. <i>Biology of Reproduction</i> , 1996, 55, 567-574.	2.7	131
38	Comparative Effectiveness of Prostate Cancer Treatments: Evaluating Statistical Adjustments for Confounding in Observational Data. <i>Journal of the National Cancer Institute</i> , 2010, 102, 1780-1793.	6.3	131
39	Salvage Radical Prostatectomy: Quality of Life Outcomes and Long-Term Oncological Control of Radiorecurrent Prostate Cancer. <i>Journal of Urology</i> , 2006, 176, 2025-2032.	0.4	126
40	The prostate cancer conundrum revisited. <i>Cancer</i> , 2012, 118, 5955-5963.	4.1	125
41	13-Year Outcomes Following Treatment for Clinically Localized Prostate Cancer in a Population Based Cohort. <i>Journal of Urology</i> , 2007, 177, 932-936.	0.4	124
42	Determining Cause of Death in Prostate Cancer: Are Death Certificates Valid?. <i>Journal of the National Cancer Institute</i> , 2001, 93, 1822-1823.	6.3	121
43	5-Year Urinary and Sexual Outcomes After Radical Prostatectomy: Results From the Prostate Cancer Outcomes Study. <i>Journal of Urology</i> , 2008, 179, S40-4.	0.4	117
44	Renal cell cancer histological subtype distribution differs by race and sex. <i>BJU International</i> , 2016, 117, 260-265.	2.5	115
45	Evaluating Localized Prostate Cancer and Identifying Candidates for Focal Therapy. <i>Urology</i> , 2008, 72, S12-S24.	1.0	114
46	Ureteroenteric Anastomotic Strictures After Radical Cystectomyâ€”Does Operative Approach Matter?. <i>Journal of Urology</i> , 2013, 189, 541-547.	0.4	113
47	Effect of the USPSTF Grade D Recommendation against Screening for Prostate Cancer on Incident Prostate Cancer Diagnoses in the United States. <i>Journal of Urology</i> , 2015, 194, 1587-1593.	0.4	113
48	Cardiovascular Effects of Androgen Deprivation Therapy for the Treatment of Prostate Cancer. <i>Circulation</i> , 2016, 133, 537-541.	1.6	111
49	Health Related Quality of Life for Men Treated for Localized Prostate Cancer With Long-Term Followup. <i>Journal of Urology</i> , 2010, 183, 2206-2212.	0.4	110
50	Comparison of complications after radical and partial nephrectomy: results from the National Veterans Administration Surgical Quality Improvement Program. <i>BJU International</i> , 2001, 86, 782-789.	2.5	109
51	National Trends in the Use of Partial Nephrectomy: A Rising Tide That Has Not Lifted All Boats. <i>Journal of Urology</i> , 2012, 187, 816-821.	0.4	109
52	Prostate Cancer Survivorship Care Guideline: American Society of Clinical Oncology Clinical Practice Guideline Endorsement. <i>Journal of Clinical Oncology</i> , 2015, 33, 1078-1085.	1.6	108
53	Epidemiology of Stress Urinary Incontinence in Women. <i>Current Urology Reports</i> , 2011, 12, 370-376.	2.2	104
54	LONG-TERM EFFECTS OF FINASTERIDE ON PROSTATE SPECIFIC ANTIGEN LEVELS: RESULTS FROM THE PROSTATE CANCER PREVENTION TRIAL. <i>Journal of Urology</i> , 2005, 174, 877-881.	0.4	101

#	ARTICLE	IF	CITATIONS
55	HEALTH RELATED QUALITY OF LIFE DIFFERENCES BETWEEN BLACK AND WHITE MEN WITH PROSTATE CANCER: DATA FROM THE CANCER OF THE PROSTATE STRATEGIC UROLOGIC RESEARCH ENDEAVOR. Journal of Urology, 2001, 166, 2281-2285.	0.4	99
56	Impact of Ethnicity on Primary Treatment Choice and Mortality in Men With Prostate Cancer: Data From CaPSURE. Journal of Clinical Oncology, 2010, 28, 1069-1074.	1.6	99
57	Predicting the Probability of 90-Day Survival of Elderly Patients With Bladder Cancer Treated With Radical Cystectomy. Journal of Urology, 2011, 186, 829-834.	0.4	97
58	The Hemodynamic Pathophysiology of Impotence Following Blunt Trauma to the Erect Penis. Journal of Urology, 1992, 148, 1171-1180.	0.4	96
59	The Effectiveness of Screening for Prostate Cancer. Archives of Internal Medicine, 2006, 166, 38.	3.8	94
60	Survivorship and Improving Quality of Life in Men with Prostate Cancer. European Urology, 2015, 68, 374-383.	1.9	91
61	Development of a Standardized Set of Patient-centered Outcomes for Advanced Prostate Cancer: An International Effort for a Unified Approach. European Urology, 2015, 68, 891-898.	1.9	91
62	Epidemiology of Vocal Fold Paralysis after Total Thyroidectomy for Well-Differentiated Thyroid Cancer in a Medicare Population. Otolaryngology - Head and Neck Surgery, 2014, 150, 548-557.	1.9	90
63	Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncology, The, 2019, 20, 556-569.	10.7	90
64	Racial disparity in primary and adjuvant treatment for nonmetastatic prostate cancer: SEER-Medicare trends 1991 to 1999. Urology, 2004, 64, 1171-1176.	1.0	89
65	Urinary Functional Outcome Following Radical Cystoprostatectomy and Ileal Neobladder Reconstruction in Male Patients. Journal of Urology, 2013, 189, 1782-1788.	0.4	89
66	Mortality After Radical Prostatectomy or External Beam Radiotherapy for Localized Prostate Cancer. Journal of the National Cancer Institute, 2013, 105, 711-718.	6.3	89
67	Impact of PSA Screening on the Incidence of Advanced Stage Prostate Cancer in the United States: A Surveillance Modeling Approach. Medical Decision Making, 2008, 28, 323-331.	2.4	88
68	Long-Term Oncological Outcomes in Women Undergoing Radical Cystectomy and Orthotopic Diversion for Bladder Cancer. Journal of Urology, 2009, 181, 2052-2059.	0.4	87
69	Internet Health Resources and the Cancer Patient. Cancer Investigation, 2008, 26, 202-207.	1.3	86
70	The relationship between perioperative blood transfusion and overall mortality in patients undergoing radical cystectomy for bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 871-877.	1.6	86
71	Recent Changes in Prostate Cancer Screening Practices and Epidemiology. Journal of Urology, 2017, 198, 1230-1240.	0.4	85
72	Psychological Impact of Erectile Dysfunction: Validation of a New Health Related Quality of Life Measure for Patients With Erectile Dysfunction. Journal of Urology, 2002, 168, 2086-2091.	0.4	82

#	ARTICLE	IF	CITATIONS
73	The Association Between Diffusion of the Surgical Robot and Radical Prostatectomy Rates. Medical Care, 2011, 49, 333-339.	2.4	82
74	Treatment Decision Regret Among Long-Term Survivors of Localized Prostate Cancer: Results From the Prostate Cancer Outcomes Study. Journal of Clinical Oncology, 2017, 35, 2306-2314.	1.6	81
75	Effect of Intensive Glycemic Therapy on Erectile Function in Men With Type 1 Diabetes. Journal of Urology, 2011, 185, 1828-1834.	0.4	80
76	Trends in the treatment of localized prostate cancer using supplemented cancer registry data. BJU International, 2011, 107, 576-584.	2.5	80
77	Voice-Related Patient-Reported Outcome Measures: A Systematic Review of Instrument Development and Validation. Journal of Speech, Language, and Hearing Research, 2017, 60, 62-88.	1.6	80
78	Survival of African-American and Caucasian men after sipuleucel-T immunotherapy: outcomes from the PROCEED registry. Prostate Cancer and Prostatic Diseases, 2020, 23, 517-526.	3.9	80
79	Cost of New Technologies in Prostate Cancer Treatment: Systematic Review of Costs and Cost Effectiveness of Robotic-assisted Laparoscopic Prostatectomy, Intensity-modulated Radiotherapy, and Proton Beam Therapy. European Urology, 2017, 72, 712-735.	1.9	79
80	VALIDATION OF INCREASING PROSTATE SPECIFIC ANTIGEN AS A PREDICTOR OF PROSTATE CANCER DEATH AFTER TREATMENT OF LOCALIZED PROSTATE CANCER WITH SURGERY OR RADIATION. Journal of Urology, 2004, 171, 2221-2225.	0.4	78
81	Oxidative Stress Measured by Urine F2-Isoprostane Level is Associated With Prostate Cancer. Journal of Urology, 2011, 185, 2102-2107.	0.4	76
82	Checklist to operationalize measurement characteristics of patient-reported outcome measures. Systematic Reviews, 2016, 5, 129.	5.3	75
83	Prostate Cancer on the Internet—Information or Misinformation?. Journal of Urology, 2006, 175, 1836-1842.	0.4	74
84	Hospital-Physician Consolidation Accelerated In The Past Decade In Cardiology, Oncology. Health Affairs, 2018, 37, 1123-1127.	5.2	74
85	The effect of health insurance status on the treatment and outcomes of patients with colorectal cancer. Journal of Surgical Oncology, 2014, 110, 227-232.	1.7	72
86	ORIGINAL RESEARCH—ERECTILE DYSFUNCTION: Clinical and Psychosocial Characteristics of Men with Erectile Dysfunction: Baseline Data from ExCEED. Journal of Sexual Medicine, 2006, 3, 1059-1067.	0.6	71
87	Clinical Outcomes and Recurrence Predictors of Lymph Node Positive Urothelial Cancer After Cystectomy. Journal of Urology, 2009, 182, 2182-2187.	0.4	70
88	Salvage Robotic Assisted Laparoscopic Radical Prostatectomy: A Single Institution, 5-Year Experience. Journal of Urology, 2013, 189, 507-513.	0.4	70
89	Pathological Guidelines for Orthotopic Urinary Diversion in Women With Bladder Cancer: A Review of the Literature. Journal of Urology, 2007, 178, 756-760.	0.4	69
90	Racial/Ethnic Differences in Functional Outcomes in the 5 Years After Diagnosis of Localized Prostate Cancer. Journal of Clinical Oncology, 2004, 22, 4193-4201.	1.6	67

#	ARTICLE	IF	CITATIONS
91	Lifetime implications and cost-effectiveness of using finasteride to prevent prostate cancer. American Journal of Medicine, 2005, 118, 850-857.	1.5	67
92	Incidence and predictors of understaging in patients with clinical $T \leq 1$ urothelial carcinoma undergoing radical cystectomy. BJU International, 2014, 113, 894-899.	2.5	67
93	A Clinician's Guide to Next Generation Imaging in Patients With Advanced Prostate Cancer (RADAR III). Journal of Urology, 2019, 201, 682-692.	0.4	67
94	Prostate Cancer. Journal of Urology, 2007, 177, 2020-2029.	0.4	65
95	Cross-sectional and longitudinal comparisons of health-related quality of life between patients with prostate carcinoma and matched controls. Cancer, 2004, 101, 2011-2019.	4.1	64
96	Phase III Prevention Trial of Fenretinide in Patients with Resected Non-Muscle-Invasive Bladder Cancer. Clinical Cancer Research, 2008, 14, 224-229.	7.0	63
97	Longitudinal Differences in Disease Specific Quality of Life in Men With Erectile Dysfunction: Results From the Exploratory Comprehensive Evaluation of Erectile Dysfunction Study. Journal of Urology, 2003, 169, 1437-1442.	0.4	62
98	Quality of life after treatment for prostate cancer. Current Urology Reports, 2003, 4, 185-195.	2.2	61
99	How Well Does The Partin Nomogram Predict Pathological Stage After Radical Prostatectomy In A Community Based Population? Results Of The Cancer Of The Prostate Strategic Urological Research Endeavor. Journal of Urology, 2002, 167, 1653-1658.	0.4	59
100	Using a population-based observational cohort study to address difficult comparative effectiveness research questions: the CEASAR study. Journal of Comparative Effectiveness Research, 2013, 2, 445-460.	1.4	59
101	Urinary Diversion: How Experts Divert. Urology, 2015, 85, 233-238.	1.0	59
102	Adrenal Control of Erectile Function and Nitric Oxide Synthase in the Rat Penis*. Endocrinology, 1997, 138, 3925-3932.	2.8	58
103	Differences in health-related quality of life of prostate cancer patients based on stage of cancer. Psycho-Oncology, 2004, 13, 800-807.	2.3	58
104	Evaluating Use Patterns of and Adherence to Medications for Benign Prostatic Hyperplasia. Journal of Urology, 2009, 181, 2214-2222.	0.4	58
105	Psychometric Characteristics of a Condition-specific, Health-related Quality-of-life Survey: The FACT-Vanderbilt Cystectomy Index. Urology, 2012, 80, 77-83.	1.0	58
106	Effectiveness of Hormonal and Surgical Therapies for Cryptorchidism: A Systematic Review. Pediatrics, 2013, 131, e1897-e1907.	2.1	58
107	Volume Outcomes of Cystectomy—Is it the Surgeon or the Setting?. Journal of Urology, 2012, 188, 2139-2144.	0.4	57
108	The Cost-Effectiveness of Treatment for Varicocele Related Infertility. Journal of Urology, 2002, 168, 2490-2494.	0.4	56

#	ARTICLE	IF	CITATIONS
109	Obesity, Physical Activity and Lower Urinary Tract Symptoms: Results From the Southern Community Cohort Study. <i>Journal of Urology</i> , 2011, 186, 2316-2322.	0.4	56
110	Prostate Cancer Registries: Current Status and Future Directions. <i>European Urology</i> , 2016, 69, 998-1012.	1.9	56
111	DOES SITE SPECIFIC LABELING OF SEXTANT BIOPSY CORES PREDICT THE SITE OF EXTRACAPSULAR EXTENSION IN RADICAL PROSTATECTOMY SURGICAL SPECIMEN?. <i>Journal of Urology</i> , 1999, 162, 1352-1357.	0.4	55
112	Sensitivity of Medicare Claims to Identify Cancer Recurrence in Elderly Colorectal and Breast Cancer Patients. <i>Medical Care</i> , 2016, 54, e47-e54.	2.4	55
113	The Impact of Health Literacy on Surgical Outcomes Following Radical Cystectomy. <i>Journal of Health Communication</i> , 2016, 21, 99-104.	2.4	55
114	Insulin-like growth factor-1, insulin-like growth factor binding protein-3 and risk of benign prostate hyperplasia in the prostate cancer prevention trial. <i>Prostate</i> , 2008, 68, 1477-1486.	2.3	54
115	Patient-Reported Outcome Measures Related to Laryngopharyngeal Reflux. <i>Otolaryngology - Head and Neck Surgery</i> , 2016, 155, 923-935.	1.9	54
116	Prostate Size as a Predictor of Gleason Score Upgrading in Patients With Low Risk Prostate Cancer. <i>Journal of Urology</i> , 2011, 186, 2221-2227.	0.4	53
117	Perioperative Oral Nutrition Supplementation Reduces Prevalence of Sarcopenia following Radical Cystectomy: Results of a Prospective Randomized Controlled Trial. <i>Journal of Urology</i> , 2019, 201, 470-477.	0.4	51
118	Is Quality of Life Different for Men with Erectile Dysfunction and Prostate Cancer Compared to Men with Erectile Dysfunction Due to Other Causes? Results from the ExCEED Data Base. <i>Journal of Urology</i> , 2003, 169, 1458-1461.	0.4	50
119	Obesity, body composition, and prostate cancer. <i>BMC Cancer</i> , 2012, 12, 23.	2.6	50
120	The Comparative Harms of Open and Robotic Prostatectomy in Population Based Samples. <i>Journal of Urology</i> , 2016, 195, 321-329.	0.4	50
121	Association between race and follow-up diagnostic care after a positive prostate cancer screening test in the Prostate, Lung, Colorectal, and Ovarian cancer screening trial. <i>Cancer</i> , 2013, 119, 2223-2229.	4.1	49
122	Increasing Use of Observation among Men at Low Risk for Prostate Cancer Mortality. <i>Journal of Urology</i> , 2015, 193, 801-806.	0.4	49
123	The Effect of Nerve Sparing Status on Sexual and Urinary Function: 3-Year Results from the CEASAR Study. <i>Journal of Urology</i> , 2018, 199, 1202-1209.	0.4	49
124	Real-world outcomes of sipuleucel-L treatment in PROCEED, a prospective registry of men with metastatic castration-resistant prostate cancer. <i>Cancer</i> , 2019, 125, 4172-4180.	4.1	49
125	On the Importance of Race, Socioeconomic Status and Comorbidity When Evaluating Quality of Life in Men With Prostate Cancer. <i>Journal of Urology</i> , 2007, 177, 1992-1999.	0.4	48
126	Invasive T1 bladder cancer: indications and rationale for radical cystectomy. <i>BJU International</i> , 2008, 102, 270-275.	2.5	46

#	ARTICLE	IF	CITATIONS
127	Provider and partner interactions in the treatment decision-making process for newly diagnosed localized prostate cancer. BJU International, 2011, 108, 851-856.	2.5	46
128	Racial variation in the quality of surgical care for bladder cancer. Cancer, 2014, 120, 1018-1025.	4.1	46
129	Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Prostate Cancer. Journal of Urology, 2021, 205, 769-779.	0.4	45
130	Association of Treatment Modality, Functional Outcomes, and Baseline Characteristics With Treatment-Related Regret Among Men With Localized Prostate Cancer. JAMA Oncology, 2022, 8, 50.	7.1	45
131	Quality of Life Issues in Bladder Cancer Patients Following Cystectomy and Urinary Diversion. Urologic Clinics of North America, 2005, 32, 207-216.	1.8	44
132	Trends in Treatment Costs for Localized Prostate Cancer. Medical Care, 2007, 45, 154-159.	2.4	44
133	Lymph Node Yield at Radical Cystectomy Predicts Mortality in Node-negative and not Node-positive Patients. Urology, 2012, 80, 632-640.	1.0	44
134	What If I Don't Treat My PSA-Detected Prostate Cancer? Answers from Three Natural History Models. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 740-750.	2.5	43
135	The Population Level Prevalence and Correlates of Appropriate and Inappropriate Imaging to Stage Incident Prostate Cancer in the Medicare Population. Journal of Urology, 2012, 187, 97-102.	0.4	42
136	Predictors of Intravesical Therapy for Nonmuscle Invasive Bladder Cancer: Results From the Surveillance, Epidemiology and End Results Program 2003 Patterns of Care Project. Journal of Urology, 2008, 180, 520-524.	0.4	41
137	Assessment of Patient Experience With Unilateral Vocal Fold Immobility: A Preliminary Study. Journal of Voice, 2014, 28, 636-643.	1.5	41
138	Urinary functional outcomes in female neobladder patients. World Journal of Urology, 2014, 32, 221-228.	2.2	41
139	Racial variation in the pattern and quality of care for prostate cancer in the USA: mind the gap. BJU International, 2010, 106, 322-328.	2.5	39
140	Magnetic Resonance Imaging for Locating Nonpalpable Undescended Testicles: A Meta-analysis. Pediatrics, 2013, 131, e1908-e1916.	2.1	39
141	Twitter response to the United States Preventive Services Task Force recommendations against screening with prostate-specific antigen. BJU International, 2015, 116, 65-71.	2.5	39
142	Sociodemographic and Clinical Risk Characteristics of Patients With Prostate Cancer Within the Veterans Affairs Health Care System: Data From CaPSURE. Journal of Urology, 2003, 170, 905-908.	0.4	38
143	Impact of Prostate Cancer on Sexual Relationships: A Longitudinal Perspective on Intimate Partners' Experiences. Journal of Sexual Medicine, 2013, 10, 3135-3143.	0.6	38
144	Contemporary prevalence of pretreatment urinary, sexual, hormonal, and bowel dysfunction: Defining the population at risk for harms of prostate cancer treatment. Cancer, 2014, 120, 1263-1271.	4.1	38

#	ARTICLE	IF	CITATIONS
145	Preliminary treatment considerations among men with newly diagnosed prostate cancer. American Journal of Managed Care, 2010, 16, e121-30.	1.1	38
146	Five-year cost analysis of intra-detrusor injection of botulinum toxin type A and augmentation cystoplasty for refractory neurogenic detrusor overactivity. World Journal of Urology, 2011, 29, 51-57.	2.2	37
147	Knowledge of the harms of tobacco use among patients with bladder cancer. Cancer, 2014, 120, 3914-3922.	4.1	37
148	An Ecologic Study of Prostate-specific Antigen Screening and Prostate Cancer Mortality in Nine Geographic Areas of the United States. American Journal of Epidemiology, 2004, 160, 1059-1069.	3.4	36
149	Survival benefit associated with adjuvant androgen deprivation therapy combined with radiotherapy for high- and low-risk patients with nonmetastatic prostate cancer. International Journal of Radiation Oncology Biology Physics, 2006, 66, 395-402.	0.8	36
150	Patient preferences and urologist recommendations among local-stage prostate cancer patients who present for initial consultation and second opinions. World Journal of Urology, 2011, 29, 3-9.	2.2	36
151	Symptoms and inflammation in chronic prostatitis/chronic pelvic pain syndrome. Urology, 2002, 60, 959-963.	1.0	35
152	Erectile Aid Use by Men Treated for Localized Prostate Cancer. Journal of Urology, 2009, 182, 649-654.	0.4	35
153	Appropriate And Inappropriate Imaging Rates For Prostate Cancer Go Hand In Hand By Region, As If Set By Thermostat. Health Affairs, 2012, 31, 730-740.	5.2	35
154	Relationship of first-year costs of treating localized prostate cancer to initial choice of therapy and stage at diagnosis: results from the CaPSURE database. Urology, 2001, 57, 499-503.	1.0	34
155	The physical burden of prostate cancer. Urologic Clinics of North America, 2003, 30, 305-313.	1.8	34
156	Factors Influencing Patients' Acceptance and Adherence to Active Surveillance. Journal of the National Cancer Institute Monographs, 2012, 2012, 207-212.	2.1	34
157	Burden among partner caregivers of patients diagnosed with localized prostate cancer within 1Âyear after diagnosis: an economic perspective. Supportive Care in Cancer, 2013, 21, 3461-3469.	2.2	34
158	Factors associated with satisfaction with prostate cancer care: results from Cancer of the Prostate Strategic Urologic Research Endeavor (<scp>CaPSURE</scp>). BJU International, 2013, 111, 213-220.	2.5	34
159	Variation in the Intensity of Hematuria Evaluation: A Target for Primary Care Quality Improvement. American Journal of Medicine, 2014, 127, 633-640.e11.	1.5	34
160	Influence of Age on Incident Diabetes and Cardiovascular Disease in Prostate Cancer Survivors Receiving Androgen Deprivation Therapy. Journal of Urology, 2015, 193, 1226-1231.	0.4	34
161	Prediction of Long-term Other-cause Mortality in Men With Early-stage Prostate Cancer: Results From the Prostate Cancer Outcomes Study. Urology, 2015, 85, 92-100.	1.0	34
162	Quality of Life After Therapy for Localized Prostate Cancer. Cancer Journal (Sudbury, Mass), 2007, 13, 318-326.	2.0	33

#	ARTICLE	IF	CITATIONS
163	Prostate-sparing cystectomy: A review of the oncologic and functional outcomes. Contraindicated in patients with bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2009, 27, 466-472.	1.6	33
164	Comparative Analysis of Biopsy Upgrading in Four Prostate Cancer Active Surveillance Cohorts. <i>Annals of Internal Medicine</i> , 2018, 168, 1.	3.9	33
165	Regional Variation in Total Cost per Radical Prostatectomy in the Healthcare Cost and Utilization Project Nationwide Inpatient Sample Database. <i>Journal of Urology</i> , 2010, 183, 1504-1509.	0.4	32
166	Pelvic organ prolapse (POP) surgery: the evidence for the repairs. <i>BJU International</i> , 2011, 107, 1704-1719.	2.5	32
167	The Cancer Survival Query System: Making survival estimates from the Surveillance, Epidemiology, and End Results program more timely and relevant for recently diagnosed patients. <i>Cancer</i> , 2012, 118, 5652-5662.	4.1	32
168	THE RELATIONSHIP AMONG LOWER URINARY TRACT SYMPTOMS, PROSTATE SPECIFIC ANTIGEN AND ERECTILE DYSFUNCTION IN MEN WITH BENIGN PROSTATIC HYPERPLASIA: RESULTS FROM THE PROSCAR LONG-TERM EFFICACY AND SAFETY STUDY. <i>Journal of Urology</i> , 2005, 173, 903-907.	0.4	31
169	Immediate effects of the initial FDA notification on the use of surgical mesh for pelvic organ prolapse surgery in medicare beneficiaries. <i>Neurourology and Urodynamics</i> , 2013, 32, 330-335.	1.5	31
170	Effect of injection augmentation on need for framework surgery in unilateral vocal fold paralysis. <i>Laryngoscope</i> , 2016, 126, 128-134.	2.0	31
171	Sexual Dysfunction and Symptom Impact in Men with Long-Standing Type 1 Diabetes in the DCCT/EDIC Cohort. <i>Journal of Sexual Medicine</i> , 2009, 6, 1969-1978.	0.6	30
172	Effect of Prostate Cancer Severity on Functional Outcomes After Localized Treatment: Comparative Effectiveness Analysis of Surgery and Radiation Study Results. <i>European Urology</i> , 2018, 74, 26-33.	1.9	30
173	Surgeon Participation in Early Accountable Care Organizations. <i>Annals of Surgery</i> , 2018, 267, 401-407.	4.2	30
174	Financial Toxicity Among Patients with Prostate, Bladder, and Kidney Cancer: A Systematic Review and Call to Action. <i>European Urology Oncology</i> , 2021, 4, 396-404.	5.4	30
175	THE ECONOMIC BURDEN OF METASTATIC AND PROSTATE SPECIFIC ANTIGEN PROGRESSION IN PATIENTS WITH PROSTATE CANCER: FINDINGS FROM A RETROSPECTIVE ANALYSIS OF HEALTH PLAN DATA. <i>Journal of Urology</i> , 2004, 171, 2250-2254.	0.4	29
176	Prostate Cancer: Epidemiology and Health-related Quality of Life. <i>Urology</i> , 2008, 72, S3-S11.	1.0	29
177	Centralization of Radical Prostatectomy in the United States. <i>Journal of Urology</i> , 2013, 189, 500-506.	0.4	29
178	Medicare Accountable Care Organization Enrollment and Appropriateness of Cancer Screening. <i>JAMA Internal Medicine</i> , 2018, 178, 648.	5.1	29
179	THE COST-EFFECTIVENESS OF COMBINED ANDROGEN BLOCKADE WITH BICALUTAMIDE AND LUTEINIZING HORMONE RELEASING HORMONE AGONIST IN MEN WITH METASTATIC PROSTATE CANCER. <i>Journal of Urology</i> , 2005, 174, 547-552.	0.4	28
180	Association Between Socioeconomic Status (SES) and Lower Urinary Tract Symptom (LUTS) Severity Among Black and White Men. <i>Journal of General Internal Medicine</i> , 2011, 26, 1305-1310.	2.6	28

#	ARTICLE	IF	CITATIONS
181	Trends in the use of evidence-based therapy for resectable gastric cancer. Journal of Surgical Oncology, 2014, 110, 285-290.	1.7	28
182	Gender, Race, and Variation in the Evaluation of Microscopic Hematuria Among Medicare Beneficiaries. Journal of General Internal Medicine, 2015, 30, 440-447.	2.6	28
183	The State of the Science on Prostate Cancer Biomarkers: The San Francisco Consensus Statement. European Urology, 2019, 76, 268-272.	1.9	28
184	Access to Information Sources and Treatment Considerations Among Men With Local Stage Prostate Cancer. Urology, 2009, 74, 509-515.	1.0	27
185	Efficacy of Intermittent Androgen Deprivation Therapy vs Conventional Continuous Androgen Deprivation Therapy for Advanced Prostate Cancer: A Meta-analysis. Urology, 2013, 82, 327-334.	1.0	27
186	Biochemical Recurrence-free Survival After Robotic-assisted Laparoscopic vs Open Radical Prostatectomy for Intermediate- and High-risk Prostate Cancer. Urology, 2014, 83, 1309-1315.	1.0	27
187	Treatment of a population based sample of men diagnosed with testicular cancer in the United States. Urologic Oncology: Seminars and Original Investigations, 2009, 27, 604-610.	1.6	26
188	A 22 Gene-expression Assay, Decipher® (GenomeDx Biosciences) to Predict Five-year Risk of Metastatic Prostate Cancer in Men Treated with Radical Prostatectomy. PLOS Currents, 2015, 7, .	1.4	26
189	Urologist-Level Correlation in the Use of Observation for Low- and High-Risk Prostate Cancer. JAMA Surgery, 2017, 152, 27.	4.3	25
190	Racial Variation in the Quality of Surgical Care for Prostate Cancer. Journal of Urology, 2012, 188, 1279-1285.	0.4	24
191	Prostate Cancer Survivorship Care Guidelines: American Society of Clinical Oncology Practice Guideline Endorsement. Journal of Oncology Practice, 2015, 11, e445-e449.	2.5	24
192	Racial disparities in mortality for patients with prostate cancer after radical prostatectomy. Cancer, 2021, 127, 1517-1528.	4.1	24
193	Quality of Life with Advanced Metastatic Prostate Cancer. Urologic Clinics of North America, 2012, 39, 505-515.	1.8	23
194	Self-Reported Health Status Predicts Other-Cause Mortality in Men with Localized Prostate Cancer: Results from the Prostate Cancer Outcomes Study. Journal of General Internal Medicine, 2015, 30, 924-934.	2.6	23
195	The Pendulum of Prostate Cancer Screening. JAMA - Journal of the American Medical Association, 2015, 314, 2031.	7.4	23
196	Oncologic Outcomes after Anterior Exenteration for Muscle Invasive Bladder Cancer in Women. Journal of Urology, 2016, 196, 1030-1035.	0.4	23
197	The Development of a Telemedical Cancer Center within the Veterans Affairs Health Care System: A Report of Preliminary Clinical Results. Telemedicine Journal and E-Health, 2002, 8, 123-130.	2.8	22
198	Lessons learnt about early prostate cancer from large scale databases: population-based pearls of wisdom. Surgical Oncology, 2002, 11, 3-11.	1.6	22

#	ARTICLE	IF	CITATIONS
199	Longitudinal Differences in Psychological Outcomes for Men with Erectile Dysfunction: Results from ExCEED TM. Journal of Sexual Medicine, 2006, 3, 1068-1076.	0.6	22
200	Diabetes mellitus and health-related quality of life in prostate cancer: 5-year results from the Prostate Cancer Outcomes Study. BJU International, 2011, 107, 1223-1231.	2.5	22
201	Successful external validation of a model to predict other cause mortality in localized prostate cancer. BMC Medicine, 2016, 14, 25.	5.5	22
202	Variation in the Diagnostic Evaluation among Persons with Hematuria: Influence of Gender, Race and Risk Factors for Bladder Cancer. Journal of Urology, 2017, 198, 1033-1038.	0.4	22
203	Racial Variation in the Incidence of Squamous Cell Carcinoma of the Bladder in the United States. Journal of Urology, 2002, 168, 1960-1963.	0.4	21
204	Long-term outcome in patients with a Gleason score ≤ 6 prostate cancer treated by radical prostatectomy. BJU International, 2011, 108, 660-664.	2.5	21
205	Patient-Reported Financial Toxicity Associated with Contemporary Treatment for Localized Prostate Cancer. Journal of Urology, 2021, 205, 761-768.	0.4	21
206	Quality of life in patients with localized prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2005, 23, 208-215.	1.6	20
207	Risks of Serious Toxicities from Intermittent versus Continuous Androgen Deprivation Therapy for Advanced Prostate Cancer: A Population Based Study. Journal of Urology, 2017, 197, 1251-1257.	0.4	20
208	An update on randomized clinical trials in localized and locoregional prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2005, 23, 280-288.	1.6	19
209	Health-related quality of life for men with prostate cancer and diabetes: A longitudinal analysis from CaPSURE. Urology, 2006, 68, 1242-1247.	1.0	19
210	Comparison of the International Index of Erectile Function erectile domain scores and nocturnal penile tumescence and rigidity measurements: does one predict the other?. BJU International, 2006, 98, 105-109.	2.5	19
211	Impact of Complications and Hospital-Free Days on Health Related Quality of Life 1 Year after Radical Cystectomy. Journal of Urology, 2014, 192, 1360-1364.	0.4	19
212	Racial Variation in Patient-Reported Outcomes Following Treatment for Localized Prostate Cancer: Results from the CEASAR Study. European Urology, 2017, 72, 307-314.	1.9	19
213	Race independently predicts prostate specific antigen testing frequency following a prostate carcinoma diagnosis. Cancer, 2003, 98, 496-503.	4.1	18
214	Patterns and Predictors of Urodynamics Use in the United States. Journal of Urology, 2013, 189, 1791-1796.	0.4	18
215	The Power and the Peril of Large Administrative Databases. Journal of Urology, 2015, 194, 10-11.	0.4	18
216	The comparative oncologic effectiveness of available management strategies for clinically localized prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 51-58.	1.6	18

#	ARTICLE	IF	CITATIONS
217	The Influence of Psychosocial Constructs on the Adherence to Active Surveillance for Localized Prostate Cancer in a Prospective, Population-based Cohort. <i>Urology</i> , 2017, 103, 173-178.	1.0	18
218	Predictors of Overall and Cancer-Free Survival of Patients With Localized Prostate Cancer Treated With Primary Androgen Suppression Therapy: Results From the Prostate Cancer Outcomes Study. <i>Journal of Urology</i> , 2007, 177, 1307-1312.	0.4	17
219	Considering racial and ethnic preferences in communication and interactions among the patient, family member, and physician following diagnosis of localized prostate cancer: study of a US population. <i>International Journal of General Medicine</i> , 2011, 4, 481.	1.8	17
220	Quality of Life After Sipuleucel-T Therapy: Results From a Randomized, Double-blind Study in Patients With Androgen-dependent Prostate Cancer. <i>Urology</i> , 2013, 82, 410-415.	1.0	17
221	The Patient Protection and Affordable Care Act: The impact on urologic cancer care. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013, 31, 980-984.	1.6	17
222	The cost-effectiveness of treatment for varicocele related infertility. <i>Journal of Urology</i> , 2002, 168, 2490-4.	0.4	17
223	Steroid hormones and hormone-related genetic and lifestyle characteristics as risk factors for benign prostatic hyperplasia: Review of epidemiologic literature. <i>Urology</i> , 2004, 64, 201-211.	1.0	16
224	TPX2 as a prognostic indicator and potential therapeutic target in clear cell renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 286-293.	1.6	16
225	Patient-Reported Outcome Measures in Upper Airway-Related Dyspnea. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2017, 143, 824.	2.2	16
226	Therapeutic Ultrasound and Prostate Cancer. <i>Seminars in Interventional Radiology</i> , 2017, 34, 187-200.	0.8	16
227	Segmental Testicular Infarction in the Neonate: A Case Report. <i>Journal of Urology</i> , 1995, 153, 1992-1993.	0.4	15
228	The Evolution of Self-Reported Urinary and Sexual Dysfunction over the Last Two Decades: Implications for Comparative Effectiveness Research. <i>European Urology</i> , 2015, 67, 1019-1025.	1.9	15
229	Racial variation in receipt of quality radiation therapy for prostate cancer. <i>Cancer Causes and Control</i> , 2018, 29, 895-899.	1.8	15
230	Is combined androgen blockade with bicalutamide cost-effective compared with combined androgen blockade with flutamide?. <i>Urology</i> , 2005, 66, 835-839.	1.0	14
231	Pay for Performance: Rationale and Potential Implications for Urology. <i>Journal of Urology</i> , 2007, 178, 402-408.	0.4	14
232	Doing More for More: Unintended Consequences of Financial Incentives for Oncology Specialty Care. <i>Journal of the National Cancer Institute</i> , 2016, 108, .	6.3	14
233	Urinary retention and catheter use among U.S. female Medicare beneficiaries: Prevalence and risk factors. <i>Neurourology and Urodynamics</i> , 2017, 36, 2101-2108.	1.5	14
234	Information Seeking and Satisfaction with Information Sources Among Spouses of Men with Newly Diagnosed Local-Stage Prostate Cancer. <i>Journal of Cancer Education</i> , 2018, 33, 325-331.	1.3	14

#	ARTICLE	IF	CITATIONS
235	Decision-making processes among men with low-risk prostate cancer: A survey study. <i>Psycho-Oncology</i> , 2018, 27, 325-332.	2.3	14
236	Assessing the quality of prostate cancer care. <i>Current Opinion in Urology</i> , 2008, 18, 297-302.	1.8	13
237	Choledocholithiasis Management in Rural America: Health Disparity or Health Opportunity?. <i>Journal of Surgical Research</i> , 2011, 170, 214-219.	1.6	13
238	Patient-Reported Outcome Measures in Colon and Rectal Surgery: A Systematic Review and Quality Assessment. <i>Diseases of the Colon and Rectum</i> , 2020, 63, 1156-1167.	1.3	13
239	Combining longitudinal studies of PSA. <i>Biostatistics</i> , 2004, 5, 483-500.	1.5	13
240	EFFECT OF CRYPTORCHIDISM ON TESTICULAR HISTOLOGY IN A NATURALLY CRYPTORCHID ANIMAL MODEL. <i>Journal of Urology</i> , 1997, 158, 1978-1982.	0.4	12
241	The Politics of Prostate Cancer Screening. <i>Urologic Clinics of North America</i> , 2014, 41, 249-255.	1.8	12
242	Impact of Adherence to Quality Measures for Localized Prostate Cancer on Patient-reported Health-related Quality of Life Outcomes, Patient Satisfaction, and Treatment-related Complications. <i>Medical Care</i> , 2016, 54, 738-744.	2.4	12
243	The association between Medicare accountable care organization enrollment and breast, colorectal, and prostate cancer screening. <i>Cancer</i> , 2018, 124, 4366-4373.	4.1	12
244	Contemporary prostate cancer radiation therapy in the United States: Patterns of care and compliance with quality measures. <i>Practical Radiation Oncology</i> , 2018, 8, 307-316.	2.1	12
245	Development and Internal Validation of a Web-based Tool to Predict Sexual, Urinary, and Bowel Function Longitudinally After Radiation Therapy, Surgery, or Observation. <i>European Urology</i> , 2020, 78, 248-255.	1.9	12
246	Willingness to Pay for Prostate Cancer Treatment among Patients and Their Family Members at 1 Year After Diagnosis. <i>Value in Health</i> , 2012, 15, 716-723.	0.3	11
247	Trends in the Multimodality Treatment of Resectable Colorectal Liver Metastases: an Underutilized Strategy. <i>Journal of Gastrointestinal Surgery</i> , 2013, 17, 1938-1946.	1.7	11
248	ABCDE Steps for Heart and Vascular Wellness Following a Prostate Cancer Diagnosis. <i>Circulation</i> , 2015, 132, e218-20.	1.6	11
249	Comparison of Patient-reported Outcomes After External Beam Radiation Therapy and Combined External Beam With Low-dose-rate Brachytherapy Boost in Men With Localized Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 116-126.	0.8	11
250	COVID-19 and financial toxicity in patients with renal cell carcinoma. <i>World Journal of Urology</i> , 2021, 39, 2559-2565.	2.2	11
251	<p>>What Do Men with Metastatic Prostate Cancer Consider When Making Treatment Decisions? A Mixed-methods Study<p>>. <i>Patient Preference and Adherence</i> , 2020, Volume 14, 1949-1959.	1.8	11
252	Treatment outcomes in localized prostate cancer: A patient-oriented approach. <i>Urologic Oncology</i> , 2002, 20, 63-73.	1.5	11

#	ARTICLE	IF	CITATIONS
253	Interpretation of Domain Scores on the EPIC®”How Does the Domain Score Translate into Functional Outcomes?. Journal of Urology, 2019, 202, 1150-1158.	0.4	11
254	Adrenal Control of Erectile Function and Nitric Oxide Synthase in the Rat Penis. Endocrinology, 1997, 138, 3925-3932.	2.8	11
255	Computer-generated graphical presentations: Use of multimedia to enhance communication. Urology, 1997, 49, 2-9.	1.0	10
256	Unanticipated and Underappreciated Outcomes During Management of Local Stage Prostate Cancer: A Prospective Survey. Journal of Urology, 2010, 184, 120-125.	0.4	10
257	Outpatient versus Inpatient Observation after Percutaneous Native Kidney Biopsy: A Cost Minimization Study. American Journal of Nephrology, 2011, 34, 64-70.	3.1	10
258	Selecting Active Surveillance: Decision Making Factors for Men with a Low-Risk Prostate Cancer. Medical Decision Making, 2019, 39, 962-974.	2.4	10
259	How well does the Partin nomogram predict pathological stage after radical prostatectomy in a community based population? Results of the cancer of the prostate strategic urological research endeavor. Journal of Urology, 2002, 167, 1653-7; discussion 1657-8.	0.4	10
260	Health Care Reform 2010: A Fresh View on Tort Reform. Journal of Urology, 2010, 184, 1840-1846.	0.4	9
261	Complementary and Alternative Medicine Use, Patient-reported Outcomes, and Treatment Satisfaction Among Men With Localized Prostate Cancer. Urology, 2012, 79, 1034-1041.	1.0	9
262	Benchmarking the Use of a Rapid Response Team by Surgical Services at a Tertiary Care Hospital. Journal of the American College of Surgeons, 2014, 218, 66-72.	0.5	9
263	Cost-effective management of pelvic fracture urethral injuries. World Journal of Urology, 2017, 35, 1617-1623.	2.2	9
264	Predictors of Response Outcomes for Research Recruitment Through a Central Cancer Registry: Evidence From 17 Recruitment Efforts for Population-Based Studies. American Journal of Epidemiology, 2019, 188, 928-939.	3.4	9
265	Prostate cancer mortality and metastasis under different biopsy frequencies in North American active surveillance cohorts. Cancer, 2020, 126, 583-592.	4.1	9
266	National Variation in Elective Colon Resection for Diverticular Disease. Annals of Surgery, 2020, Publish Ahead of Print, .	4.2	9
267	Association between Treatment for Localized Prostate Cancer and Mental Health Outcomes. Journal of Urology, 2022, 207, 1029-1037.	0.4	9
268	Comparative effectiveness research in localized prostate cancer treatment. Journal of Comparative Effectiveness Research, 2013, 2, 583-593.	1.4	8
269	Fibromyxoid Nephrogenic Adenoma in the Ureter. Journal of Endourology Case Reports, 2018, 4, 97-99.	0.3	8
270	Pharmacoeconomics of Available Treatment Options for Metastatic Prostate Cancer. Pharmacoeconomics, 2007, 25, 309-327.	3.3	7

#	ARTICLE	IF	CITATIONS
271	Canadian Consensus Conference: The FDA decision on the use of 5ARIs. Canadian Urological Association Journal, 2012, 6, 83-88.	0.6	7
272	Functional Outcomes after Treatment for Prostate Cancer. New England Journal of Medicine, 2013, 368, 1653-1654.	27.0	7
273	Effect of Age, Tumor Risk, and Comorbidity in a U.S. Population-Based Cohort of Men With Prostate Cancer. Annals of Internal Medicine, 2013, 159, 370.	3.9	7
274	Prostate Cancer Screening and the Goldilocks Principle: How Much Is Just Right?. Journal of Clinical Oncology, 2018, 36, 937-941.	1.6	7
275	MR Imaging-Guided Transurethral Ultrasound Ablation of Localized Prostate Cancer: Preliminary Experience from a Single Center in a Prospective, Multi-Center, Single-Arm Clinical Trial. Journal of Vascular and Interventional Radiology, 2020, 31, 740-746.e4.	0.5	7
276	Quality of life following prostate cancer treatments. Current Urology Reports, 2000, 1, 71-77.	2.2	6
277	Comparison of open live donor nephrectomy, laparoscopic live donor nephrectomy, and hand-assisted live donor nephrectomy: A cost-minimization analysis. Journal of Surgical Research, 2012, 176, e89-e94.	1.6	6
278	Trends in urodynamics in U.S. female medicare beneficiaries, 2000-2010. Neurourology and Urodynamics, 2015, 34, 420-423.	1.5	6
279	Adverse Events Associated with Cumulative Corticosteroid Use in Patients with Castration-Resistant Prostate Cancer: An Administrative Claims Analysis. Drug Safety, 2020, 43, 23-33.	3.2	6
280	Radiotherapy after radical prostatectomy: Effect of timing of postprostatectomy radiation on functional outcomes. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 930.e23-930.e32.	1.6	6
281	Patient expectations of benefit from systemic treatments for metastatic prostate cancer. Cancer Medicine, 2020, 9, 980-987.	2.8	6
282	Five-year outcomes from a prospective comparative effectiveness study evaluating external-beam radiotherapy with or without low-dose-rate brachytherapy boost for localized prostate cancer. Cancer, 2021, 127, 1912-1925.	4.1	6
283	Health-related quality of life (HRQoL) deterioration and pain progression in men with non-metastatic castration-resistant prostate cancer (mCRPC): Results from the PROSPER study.. Journal of Clinical Oncology, 2018, 36, 5010-5010.	1.6	6
284	Overall survival (OS) of African-American (AA) and Caucasian (CAU) men who received sipuleucel-T for metastatic castration-resistant prostate cancer (mCRPC): Final PROCEED analysis.. Journal of Clinical Oncology, 2019, 37, 5035-5035.	1.6	6
285	Assessing the Quality of Surgical Care for Clinically Localized Prostate Cancer: Results from the CEASAR Study. Journal of Urology, 2020, 204, 1236-1241.	0.4	6
286	Consistent survival benefit of enzalutamide plus androgen deprivation therapy in men with nonmetastatic castration-resistant prostate cancer: PROSPER subgroup analysis by age and region. European Journal of Cancer, 2021, 159, 237-246.	2.8	6
287	Variations in Prostate Cancer Patterns of Care: Is It the Quality of Care or the Quality of the Data?. Journal of Clinical Oncology, 2005, 23, 7783-7784.	1.6	5
288	Association of Pre-Existing Symptoms with Treatment Decisions among Newly Diagnosed Prostate Cancer Patients. Patient, 2008, 1, 189-200.	2.7	5

#	ARTICLE	IF	CITATIONS
289	Patient Recruitment Methods to Evaluate Treatment Decision Making for Localized Prostate Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2010, 33, 381-386.	1.3	5
290	Adoption of Intermittent Androgen Deprivation Therapy for Advanced Prostate Cancer: A Population Based Study in American Urology Practice. Urology Practice, 2015, 2, 190-198.	0.5	5
291	Treatment registry for outcomes in patients with castration-resistant prostate cancer (TRUMPET): a methodology for real-world evidence and research. Future Oncology, 2016, 12, 2689-2699.	2.4	5
292	Physicians's perspectives on the informational needs of low-risk prostate cancer patients. Health Education Research, 2017, 32, 134-152.	1.9	5
293	An Empiric Evaluation of the Effect of Variation in Intensity of Followup for Surgically Treated Renal Neoplasms on Cancer Specific Survival. Journal of Urology, 2017, 197, 37-43.	0.4	5
294	Modeling economic and epidemiological impact of voluntary medical male circumcision among men who have sex with men in Beijing, China. International Journal of STD and AIDS, 2019, 30, 630-638.	1.1	5
295	Characterizing Standardized Letters of Recommendation in Urology Residency Applications. Urology, 2021, 158, 18-25.	1.0	5
296	Enzalutamide versus bicalutamide in patients with nonmetastatic castration-resistant prostate cancer: a prespecified subgroup analysis of the STRIVE trial. Prostate Cancer and Prostatic Diseases, 2022, 25, 363-365.	3.9	5
297	Quality of Life Outcomes Following Treatment for Localized Prostate Cancer: What's New and What's Not. European Urology, 2017, 72, 886-887.	1.9	5
298	Men's Health. Are We Missing the Big Picture?. Journal of General Internal Medicine, 2001, 16, 717-718.	2.6	4
299	The invasive T1 bladder tumor: Contemporary issues and rationale for radical cystectomy. Current Urology Reports, 2008, 9, 179-181.	2.2	4
300	Outcomes research in urology. World Journal of Urology, 2011, 29, 1-2.	2.2	4
301	Vasculogenic Erectile Dysfunction. , 2013, , 341-348.		4
302	Re: Changes in Burnout and Satisfaction with Work-Life Balance in Physicians and the General US Working Population between 2011 and 2014. Journal of Urology, 2016, 195, 1568-1568.	0.4	4
303	Influence of the facility caseload on the subsequent survival of men with localized prostate cancer undergoing radical prostatectomy. Cancer, 2019, 125, 3853-3863.	4.1	4
304	Functional Recovery Following Primary Treatment for Prostate Cancer: Update from the CEASAR Study. European Urology Focus, 2020, 6, 205-207.	3.1	4
305	The Impact of Hospital Volume on Short-term and Long-term Outcomes for Patients Undergoing Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma. Urology, 2021, 147, 135-142.	1.0	4
306	Out-of-pocket costs for commercially insured patients with localized prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 797-805.	1.6	4

#	ARTICLE	IF	CITATIONS
307	Standardized Letters of Recommendation and Success in the Urology Match. Urology, 2022, 166, 95-97.	1.0	4
308	Male Sexual Function: A Guide to Clinical Management. Annals of Internal Medicine, 2002, 137, 300.	3.9	3
309	Medicare reimbursement changes for bladder biopsies. Cancer, 2010, 116, 1153-1154.	4.1	3
310	755 URINARY FUNCTION EVALUATION IN FEMALE CYSTECTOMY PATIENTS WITH ORTHOTOPIC DIVERSION UTILISING A VALIDATED HEALTH-RELATED QUALITY OF LIFE QUESTIONNAIRE. Journal of Urology, 2010, 183, .	0.4	3
311	Adhering To The Standard Of Care For Prostate Cancer. Health Affairs, 2012, 31, 1367-1367.	5.2	3
312	Post-prostatectomy Incontinence and Pelvic Floor Muscle Training: A Defining Problem. European Urology, 2013, 64, 773-775.	1.9	3
313	The Influence of Access Related Factors on Adherence to Clinical Practice Guidelines for Muscle Invasive Bladder Cancer. Urology Practice, 2014, 1, 127-133.	0.5	3
314	Let's Not Throw the Baby out With the Bathwater in Prostate Cancer Screening. Journal of Clinical Oncology, 2016, 34, 3489-3491.	1.6	3
315	Re: Prostate Cancer Incidence and PSA Testing Patterns in Relation to USPSTF Screening Recommendations. Journal of Urology, 2016, 196, 105-106.	0.4	3
316	Re: Annual Medical Expenditure and Productivity Loss among Colorectal, Female Breast, and Prostate Cancer Survivors in the United States. Journal of Urology, 2016, 196, 105-105.	0.4	3
317	Anticipating the Unintended Consequences of Closing the Door on Physician Self-Referral. Journal of Urology, 2016, 196, 444-450.	0.4	3
318	Re: Intermittent vs Continuous Androgen Deprivation Therapy for Prostate Cancer: A Systematic Review and Meta-Analysis. Journal of Urology, 2016, 195, 353-354.	0.4	3
319	Benchmarking patient satisfaction scores in a colorectal patient population. Surgical Endoscopy and Other Interventional Techniques, 2021, 35, 309-316.	2.4	3
320	A comparison of general, genitourinary, bowel, and sexual quality of life among long term survivors of prostate, bladder, colorectal, and lung cancer. Journal of Geriatric Oncology, 2021, 12, 305-311.	1.0	3
321	The prevention of extraction site incisional hernia after robotic-assisted radical prostatectomy. Journal of Robotic Surgery, 2021, 15, 315-317.	1.8	3
322	Active surveillance: not your father's watchful waiting. Oncology, 2009, 23, 980, 982.	0.5	3
323	Surgeons's™ Perspective of Decision Making in Recurrent Diverticulitis. Annals of Surgery Open, 2022, 3, e157.	1.4	3
324	LAPAROSCOPIC UROLOGICAL ONCOLOGY: HERE COME THE OUTCOMES!. Journal of Urology, 2005, 174, 1174-1174.	0.4	2

#	ARTICLE	IF	CITATIONS
325	Use of prostate-specific antigen in the follow-up of patients with localized prostate cancer: Results of a nationwide survey of urologists. <i>Urology</i> , 2006, 68, 80-84.	1.0	2
326	Health outcomes in older men with localized prostate cancer: Results from the Prostate Cancer Outcomes Study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2006, 24, 457.	1.6	2
327	Treatment for Postprostatectomy Incontinence. <i>JAMA - Journal of the American Medical Association</i> , 2011, 305, 197.	7.4	2
328	Editorial Comment. <i>Journal of Urology</i> , 2012, 187, 1398-1398.	0.4	2
329	Re: Short Term Outcomes of Prostate Biopsy in Men Tested for Cancer by Prostate Specific Antigen: Prospective Evaluation Within ProtecT Study. <i>Journal of Urology</i> , 2012, 188, 811-813.	0.4	2
330	Re: Black Patients More Likely than Whites to Undergo Surgery at Low-Quality Hospitals in Segregated Regions. <i>Journal of Urology</i> , 2013, 190, 2211-2211.	0.4	2
331	Time to raise the bar in localised prostate cancer. <i>BJU International</i> , 2013, 112, 278-278.	2.5	2
332	The More, The Merrier: Including a Medical Oncologist in Treatment Planning for Localized Prostate Cancer. <i>Journal of Oncology Practice</i> , 2014, 10, 113-114.	2.5	2
333	Re: Urologists' Use of Intensity-Modulated Radiation Therapy for Prostate Cancer. <i>Journal of Urology</i> , 2014, 191, 1292-1292.	0.4	2
334	Editorial Comment. <i>Urology</i> , 2016, 95, 3-4.	1.0	2
335	Re: Effectiveness of Adjuvant Chemotherapy for Locally Advanced Bladder Cancer. <i>Journal of Urology</i> , 2016, 196, 352-354.	0.4	2
336	Re: Fee-for-Service, while Much Maligned, Remains the Dominant Payment Method for Physician Visits. <i>Journal of Urology</i> , 2016, 196, 1233-1233.	0.4	2
337	Re: Sophia C. Kamran, Thomas Seisen, Sarah C. Markt, et al. Contemporary Treatment Patterns and Outcomes for Clinical Stage IS Testicular Cancer. <i>Eur Urol</i> 2018;73:262-70. <i>European Urology</i> , 2018, 73, e98-e99.	1.9	2
338	Re: Effect of Electroacupuncture on Urinary Leakage among Women with Stress Urinary Incontinence: A Randomized Clinical Trial. <i>Journal of Urology</i> , 2018, 199, 35-36.	0.4	2
339	Number-needed-to-treat analysis of clinical progression in patients with metastatic castration-resistant prostate cancer in the STRIVE and TERRAIN trials. <i>BMC Urology</i> , 2018, 18, 77.	1.4	2
340	Sexual function outcomes of radiation and androgen deprivation therapy for localized prostate cancer in men with good baseline function. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 238-247.	3.9	2
341	Association Between Surgical Volume and Survival Among Patients With Variant Histologies of Bladder Cancer. <i>Urology</i> , 2022, 159, 100-106.	1.0	2
342	Differential effect of body mass index by gender on oncological outcomes in patients with renal cell carcinoma. <i>Journal of Cancer Research and Therapeutics</i> , 2021, 17, 420.	0.9	2

#	ARTICLE	IF	CITATIONS
343	Association between health-related quality of life (HRQoL) and clinical outcomes in non-metastatic castration-resistant prostate cancer (M0 CRPC): Results from the PROSPER study.. Journal of Clinical Oncology, 2018, 36, 5043-5043.	1.6	2
344	Quality of life after treatment for prostate cancer. Current Prostate Reports, 2003, 1, 55-65.	0.1	1
345	Discussing quality-of-life issues with a patient newly diagnosed with prostate cancer. Nature Reviews Urology, 2006, 3, 449-452.	1.4	1
346	Age at surgery for undescended testis and risk of testicular cancer. Urologic Oncology: Seminars and Original Investigations, 2007, 25, 440.	1.6	1
347	Quality of life after surgery, external beam irradiation, or brachytherapy for early-stage prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2007, 25, 442-443.	1.6	1
348	Cost-effectiveness of prostate cancer chemoprevention: A quality of life-years analysis. Urologic Oncology: Seminars and Original Investigations, 2008, 26, 564-565.	1.6	1
349	Quality of life and satisfaction with outcome among prostate-cancer survivors. Urologic Oncology: Seminars and Original Investigations, 2008, 26, 565-566.	1.6	1
350	Health-related quality of life results in pathologic Stage C prostate cancer from a Southwest Oncology Group trial comparing radical prostatectomy alone with radical prostatectomy plus radiation therapy. Urologic Oncology: Seminars and Original Investigations, 2008, 26, 567-568.	1.6	1
351	Socioeconomic Factors, Urological Epidemiology and Practice Patterns. Journal of Urology, 2010, 184, 1991-1994.	0.4	1
352	Re: Supporting Informed Decision Making for Prostate Specific Antigen (PSA) Testing on the Web: An Online Randomized Controlled Trial. Journal of Urology, 2011, 185, 2158-2159.	0.4	1
353	Re: Today's "Meaningful Use" Standard for Medication Orders by Hospitals may Save Few Lives; Later Stages may do More. Journal of Urology, 2012, 187, 646-646.	0.4	1
354	Re: Physician Documentation of Fluoroscopy Time in Voiding Cystourethrography Reports Correlates With Lower Fluoroscopy Times: A Surrogate Marker of Patient Radiation Exposure. Journal of Urology, 2012, 187, 965-966.	0.4	1
355	Re: Difference in Willingness-to-Pay for Prostate Cancer Screening Between Ill-Informed and Well-Informed Men: A Contingent Valuation Survey. Journal of Urology, 2012, 187, 1273-1273.	0.4	1
356	Re: Intensity-Modulated Radiation Therapy, Proton Therapy, or Conformal Radiation Therapy and Morbidity and Disease Control in Localized Prostate Cancer. Journal of Urology, 2012, 188, 2230-2231.	0.4	1
357	Systemic therapy and the urologic oncologist: A unique opportunity for the specialty to provide comprehensive care that ultimately benefits the patient. Urologic Oncology: Seminars and Original Investigations, 2012, 30, S2-S4.	1.6	1
358	Re: Demonstration of Erectile Management Techniques to Men Scheduled for Radical Prostatectomy Reduces Long-Term Regret: A Comparative Cohort Study. Journal of Urology, 2012, 188, 1268-1269.	0.4	1
359	Re: Effect of Bothersome Overactive Bladder Symptoms on Health-Related Quality of Life, Anxiety, Depression, and Treatment Seeking in the United States: Results from EpiLUTS. Journal of Urology, 2013, 189, 1001-1001.	0.4	1
360	Re: Physicians with the Least Experience have Higher Cost Profiles than do Physicians with the Most Experience. Journal of Urology, 2013, 190, 218-218.	0.4	1

#	ARTICLE	IF	CITATIONS
361	Re: Hospital Pay-for-Performance Programs in Maryland Produced Strong Results, Including Reduced Hospital-Acquired Conditions. <i>Journal of Urology</i> , 2013, 189, 1737-1738.	0.4	1
362	Re: Association of Testosterone Therapy with Mortality, Myocardial Infarction, and Stroke in Men with Low Testosterone Levels. <i>Journal of Urology</i> , 2014, 192, 177-180.	0.4	1
363	Re: Increases in Consumer Cost Sharing Redirect Patient Volumes and Reduce Hospital Prices for Orthopedic Surgery. <i>Journal of Urology</i> , 2014, 191, 762-762.	0.4	1
364	Re: Comparative Effectiveness of Robot-Assisted and Open Radical Prostatectomy in the Postdissemination Era. <i>Journal of Urology</i> , 2014, 192, 1421-1423.	0.4	1
365	The Hidden Agenda in the Release of the Medicare Physician Reimbursement Data. <i>Urology</i> , 2014, 84, 501-502.	1.0	1
366	Re: The Impact of Health Information Technology and e-Health on the Future Demand for Physician Services. <i>Journal of Urology</i> , 2014, 192, 189-190.	0.4	1
367	Re: Variation in Surgical-Readmission Rates and Quality of Hospital Care. <i>Journal of Urology</i> , 2014, 191, 1363-1364.	0.4	1
368	Re: E-Prescribing Adoption and Use Increased Substantially Following the Start of a Federal Incentive Program. <i>Journal of Urology</i> , 2014, 191, 1364-1364.	0.4	1
369	Active Surveillance for Prostate Cancer under the Patient Protection and Affordable Care Act. <i>Urology Practice</i> , 2015, 2, 154-159.	0.5	1
370	Re: Changing Physician Incentives for Affordable, Quality Cancer Care: Results of an Episode Payment Model. <i>Journal of Urology</i> , 2015, 193, 1615-1616.	0.4	1
371	MP27-11 DISTINCT SIDE EFFECT PROFILES AFTER CONTEMPORARY TREATMENT OF LOCALIZED PROSTATE CANCER. <i>Journal of Urology</i> , 2015, 193, .	0.4	1
372	Re: Relationship between Male Pattern Baldness and the Risk of Aggressive Prostate Cancer: An Analysis of the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. <i>Journal of Urology</i> , 2015, 194, 990-991.	0.4	1
373	Re: Effect of Insurance Expansion on Utilization of Inpatient Surgery. <i>Journal of Urology</i> , 2015, 193, 256-256.	0.4	1
374	Re: Course and Predictors of Cognitive Function in Patients with Prostate Cancer Receiving Androgen-Deprivation Therapy: A Controlled Comparison. <i>Journal of Urology</i> , 2016, 195, 97-97.	0.4	1
375	Re: Physician Use of Sacral Neuromodulation among Medicare Beneficiaries with Overactive Bladder and Urinary Retention. <i>Journal of Urology</i> , 2016, 195, 689-689.	0.4	1
376	Re: Comparison of Gonadotropin-Releasing Hormone Agonists and Orchiectomy: Effects of Androgen-Deprivation Therapy. <i>Journal of Urology</i> , 2016, 196, 104-106.	0.4	1
377	Re: Financial Hardship Associated with Cancer in the United States: Findings from a Population-Based Sample of Adult Cancer Survivors. <i>Journal of Urology</i> , 2016, 196, 1234-1234.	0.4	1
378	Re: Trends in Management for Patients with Localized Prostate Cancer, 1990–2013. <i>Journal of Urology</i> , 2016, 195, 353-354.	0.4	1

#	ARTICLE	IF	CITATIONS
379	Re: Trends in National Institutes of Health Funding for Clinical Trials Registered in ClinicalTrials.gov. Journal of Urology, 2016, 195, 1567-1568.	0.4	1
380	Reply from Authors re: Julia Verne, Luke Hounsome, Roger Kockelbergh, Jem Rashbass. Improving Outcomes from Prostate Cancer: Unlocking the Treasure Trove of Information in Cancer Registries. Eur Urol 2016;69:1013-1014. European Urology, 2016, 69, 1015.	1.9	1
381	Re: Impact of Hair Removal on Surgical Site Infection Rates: A Prospective Randomized Noninferiority Trial. Journal of Urology, 2017, 197, 1462-1463.	0.4	1
382	Re: Variation and Predictors of Surgical Case Costs among Urologists. Journal of Urology, 2017, 198, 1200-1201.	0.4	1
383	Reply to M.A.N. Åžendur et al and J. Michels. Journal of Clinical Oncology, 2017, 35, 123-123.	1.6	1
384	Re: Americans Support Price Shopping for Health Care, but Few Actually Seek out Price Information. Journal of Urology, 2018, 199, 884-885.	0.4	1
385	Considering quantity and quality of life in metastatic castration-naïve prostate cancer. Lancet Oncology, The, 2018, 19, 153-154.	10.7	1
386	Patient Reported Comparative Effectiveness of Contemporary Intensity Modulated Radiation Therapy Versus External Beam Radiation Therapy of the Mid 1990s for Localized Prostate Cancer. Urology Practice, 2018, 5, 471-479.	0.5	1
387	PROSPER subgroup analysis by age and region: Overall survival and safety in men with nonmetastatic castration-resistant prostate cancer receiving androgen deprivation therapy plus enzalutamide.. Journal of Clinical Oncology, 2021, 39, 84-84.	1.6	1
388	Reply by Authors. Journal of Urology, 2021, 205, 779-779.	0.4	1
389	Assessing Quality of Life. , 2000, , 183-198.		1
390	The Impact of Prostate Cancer Diagnosis and Post-treatment Sexual Dysfunction on Quality of Life. , 2009, , 17-32.		1
391	The Cost-Effectiveness of Treatment for Varicocele Related Infertility. Journal of Urology, 2002, , 2490-2494.	0.4	1
392	Patient expectations from systemic treatment of metastatic prostate cancer (mPC).. Journal of Clinical Oncology, 2017, 35, 218-218.	1.6	1
393	Cerebrovascular event (CVE) outcome and overall survival (OS) in patients (pts) treated with sipuleucel-T (sip-T) for metastatic castration-resistant prostate cancer (mCRPC): results from the PROCEED registry.. Journal of Clinical Oncology, 2018, 36, e17018-e17018.	1.6	1
394	Creation of a standardized set of patient-centered outcomes for advanced prostate cancer: An international effort.. Journal of Clinical Oncology, 2015, 33, 282-282.	1.6	1
395	Real-world study of patients with metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide (ENZA) or abiraterone acetate plus prednisone (AA+P): Patient characteristics and treatment persistence.. Journal of Clinical Oncology, 2017, 35, e16542-e16542.	1.6	1
396	Osteoclast inhibitor treatment among men with metastatic castration-resistant prostate cancer. , 2018, 1, 2-7.		1

#	ARTICLE	IF	CITATIONS
397	Men's health. Journal of General Internal Medicine, 2001, 16, 717-718.	2.6	0
398	Pilot intervention to enhance sexual rehabilitation for couples after treatment for localized prostate carcinoma. Urologic Oncology: Seminars and Original Investigations, 2006, 24, 458.	1.6	0
399	Quality of life in prostate cancer patients taking androgen deprivation therapy. Urologic Oncology: Seminars and Original Investigations, 2006, 24, 458-459.	1.6	0
400	Quality of life in long-term survivors of bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2006, 24, 459-460.	1.6	0
401	Mortality after major surgery for urologic cancers in specialized urology hospitals: are they any better?. Urologic Oncology: Seminars and Original Investigations, 2006, 24, 460.	1.6	0
402	Survival associated with treatment vs. observation of localized prostate cancer in elderly men. Urologic Oncology: Seminars and Original Investigations, 2007, 25, 440-441.	1.6	0
403	On the importance of race, socioeconomic status, and comorbidity when evaluating quality of life in men with prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2007, 25, 441-442.	1.6	0
404	Erectile function outcome reporting after clinically localized prostate cancer treatment. Urologic Oncology: Seminars and Original Investigations, 2007, 25, 443.	1.6	0
405	Ethical Issues in Clinical Research. , 2006, , 31-46.		0
406	Diffusion of surgical innovation among patients with kidney cancer. Urologic Oncology: Seminars and Original Investigations, 2008, 26, 566-567.	1.6	0
407	Does diabetes mellitus as a comorbid condition affect the health-related quality of life in prostate cancer survivors? Results of a population-based observational study. Urologic Oncology: Seminars and Original Investigations, 2008, 26, 568.	1.6	0
408	Quality of life after radiation and androgen deprivation. Nature Reviews Urology, 2009, 6, 477-478.	3.8	0
409	Urology Board ReviewLeslieS.W.: Urology Board Review. New York: McGraw Hill Medical2009. 521 pages.. Journal of Urology, 2010, 183, 2473-2473.	0.4	0
410	Socioeconomic Factors, Urological Epidemiology and Practice Patterns. Journal of Urology, 2010, 184, 2094-2095.	0.4	0
411	Editorial Comment. Journal of Urology, 2010, 183, 2191-2192.	0.4	0
412	Re: Imaging Self-Referral Associated With Higher Costs and Limited Impact on Duration of Illness. Journal of Urology, 2011, 185, 2288-2289.	0.4	0
413	Re: Costs of Ambulatory Care Related to Female Pelvic Floor Disorders in the United States. Journal of Urology, 2011, 185, 231-232.	0.4	0
414	Re: Acquisition of MRI Equipment by Doctors Drives up Imaging Use and Spending. Journal of Urology, 2011, 185, 2289-2290.	0.4	0

#	ARTICLE	IF	CITATIONS
415	Re: Can Pelvic Floor Muscle Training Reverse Pelvic Organ Prolapse and Reduce Prolapse Symptoms? An Assessor-Blinded, Randomized, Controlled Trial. Journal of Urology, 2011, 185, 1383-1383.	0.4	0
416	Re: Complementary and Alternative Medicine (CAM) Use in Women With Pelvic Floor Disorders: A Cohort Study. Journal of Urology, 2011, 185, 1382-1383.	0.4	0
417	Re: Do Women With Overactive Bladder Have Realistic Expectations for Therapy?. Journal of Urology, 2011, 185, 1382-1382.	0.4	0
418	Re: Public Awareness of Testis Cancer and the Prevalence of Testicular Self-Examination—Changing Patterns Over 20 Years. Journal of Urology, 2011, 185, 2159-2160.	0.4	0
419	Re: Treatment Outcomes and Resource Use of Patients With Neurogenic Detrusor Overactivity Receiving Botulinum Toxin A (BOTOX) Therapy in Germany. Journal of Urology, 2011, 185, 1383-1384.	0.4	0
420	Re: Preliminary Treatment Considerations Among Men With Newly Diagnosed Prostate Cancer. Journal of Urology, 2011, 185, 898-899.	0.4	0
421	Re: The Practice of Imaging Self-Referral Doesn't Produce Much One-Stop Service. Journal of Urology, 2011, 185, 2288-2288.	0.4	0
422	Re: Cost Analysis of Interventions for Antimuscarinic Refractory Patients With Overactive Bladder. Journal of Urology, 2011, 186, 212-212.	0.4	0
423	Re: Physicians Versus Hospitals as Leaders of Accountable Care Organizations. Journal of Urology, 2011, 186, 1427-1427.	0.4	0
424	Re: Patient Preferences and Urologist Recommendations Among Local-Stage Prostate Cancer Patients who Present for Initial Consultation and Second Opinions. Journal of Urology, 2011, 186, 1877-1877.	0.4	0
425	Re: Readmissions in the Postoperative Period Following Urinary Diversion. Journal of Urology, 2011, 186, 2305-2306.	0.4	0
426	Re: Validating the Patient Safety Indicators in the Veterans Health Administration: Are They Ready for Prime Time?. Journal of Urology, 2011, 186, 2347-2348.	0.4	0
427	Re: Assessment of Quality of Cancer-Related Follow-Up Care From the Cancer Survivor's Perspective. Journal of Urology, 2011, 186, 2349-2349.	0.4	0
428	Re: Satisfaction Profiles in Men Using Intracavernosal Injection Therapy. Journal of Urology, 2012, 187, 245-246.	0.4	0
429	Re: Fifteen-Year Trend in the Use of Male Reproductive Surgery: Analysis of the Healthcare Cost and Utilization Project Data. Journal of Urology, 2012, 187, 246-246.	0.4	0
430	Re: Higher Fees Paid to US Physicians Drive Higher Spending for Physician Services Compared to Other Countries. Journal of Urology, 2012, 187, 647-648.	0.4	0
431	Re: US Physician Practices Versus Canadians: Spending Nearly Four Times as Much Money Interacting With Payers. Journal of Urology, 2012, 187, 648-648.	0.4	0
432	Re: How Well Informed are Women Who Undergo Urodynamic Testing?. Journal of Urology, 2012, 187, 965-965.	0.4	0

#	ARTICLE	IF	CITATIONS
433	Re: Urologist Compliance With AUA Best Practice Guidelines for Benign Prostatic Hyperplasia in Medicare Population. Journal of Urology, 2012, 187, 966-967.	0.4	0
434	Re: A Feasibility Study Comparing Pharmacist and Physician Recommendations for Sildenafil Treatment. Journal of Urology, 2012, 187, 1378-1379.	0.4	0
435	Re: What is the Definition of a Satisfactory Erectile Function After Bilateral Nerve Sparing Radical Prostatectomy?. Journal of Urology, 2012, 187, 1379-1379.	0.4	0
436	Re: Delivering Affordable Cancer Care in High-Income Countries. Journal of Urology, 2012, 187, 1795-1795.	0.4	0
437	Re: The Many Different Prices Paid to Providers and the Flawed Theory of Cost Shifting: Is it Time for a More Rational All-Payer System?. Journal of Urology, 2012, 187, 1796-1796.	0.4	0
438	Re: Large Variations in Medicare Payments for Surgery Highlight Savings Potential From Bundled Payment Programs. Journal of Urology, 2012, 187, 1796-1798.	0.4	0
439	Re: Cost-Effectiveness Analysis of Sacral Neuromodulation and Botulinum Toxin A Treatment for Patients With Idiopathic Overactive Bladder. Journal of Urology, 2012, 187, 2157-2158.	0.4	0
440	Re: Quality of Life in Children With Vesicoureteral Reflux as Perceived by Children and Parents. Journal of Urology, 2012, 187, 2208-2208.	0.4	0
441	Re: New American Cancer Society Process for Creating Trustworthy Cancer Screening Guidelines. Journal of Urology, 2012, 188, 560-561.	0.4	0
442	Re: Postgame Analysis: Using Video-Based Coaching for Continuous Professional Development. Journal of Urology, 2012, 188, 561-561.	0.4	0
443	Re: Understanding Variation in Primary Prostate Cancer Treatment Within the Veterans Health Administration. Journal of Urology, 2012, 188, 2230-2230.	0.4	0
444	Re: Early Prostate Cancer—Which Treatment do Men Prefer and Why?. Journal of Urology, 2012, 188, 113-113.	0.4	0
445	Re: Are Men on 5 α -Reductase Inhibitors Appropriately Referred to Urology? A Survey of Primary Care Physicians. Journal of Urology, 2012, 188, 114-114.	0.4	0
446	Re: Racial Variation in the Cost-Effectiveness of Chemotherapy for Prostate Cancer. Journal of Urology, 2012, 188, 115-115.	0.4	0
447	Re: Economic Evaluation of Everolimus Versus Sorafenib for the Treatment of Metastatic Renal Cell Carcinoma After Failure of First-Line Sunitinib. Journal of Urology, 2012, 188, 68-69.	0.4	0
448	Re: Survey Shows that at Least Some Physicians are Not Always Open or Honest with Patients. Journal of Urology, 2012, 188, 562-562.	0.4	0
449	Re: Giving Office-Based Physicians Electronic Access to Patients' Prior Imaging and Lab Results did Not Deter Ordering of Tests. Journal of Urology, 2012, 188, 562-563.	0.4	0
450	Re: Medicare's Public Reporting Initiative on Hospital Quality had Modest or No Impact on Mortality from Three Key Conditions. Journal of Urology, 2012, 188, 563-564.	0.4	0

#	ARTICLE	IF	CITATIONS
451	Re: Massachusetts Health Reforms: Uninsurance Remains Low, Self-Reported Health Status Improves as State Prepares to Tackle Costs. <i>Journal of Urology</i> , 2012, 188, 564-564.	0.4	0
452	Re: Use of Complementary and Alternative Medicine Among Men with Prostate Cancer in a Rural Setting. <i>Journal of Urology</i> , 2012, 188, 813-813.	0.4	0
453	Re: Trends in Radical Prostatectomy: Centralization, Robotics, and Access to Urologic Cancer Care. <i>Journal of Urology</i> , 2012, 188, 813-814.	0.4	0
454	Re: Lessons from a Patient Experience Survey in a Randomized Surgical Trial of Treatment of Stress Urinary Incontinence in Women. <i>Journal of Urology</i> , 2012, 188, 1234-1234.	0.4	0
455	Re: Smoking Knowledge Assessment and Cessation Trends in Patients with Bladder Cancer Presenting to a Tertiary Referral Center. <i>Journal of Urology</i> , 2012, 188, 1122-1123.	0.4	0
456	Re: Long-Term Survival Following Partial vs Radical Nephrectomy Among Older Patients with Early-Stage Kidney Cancer. <i>Journal of Urology</i> , 2012, 188, 1723-1724.	0.4	0
457	Re: Coverage of Newborn and Adult Male Circumcision Varies Among Public and Private US Payers Despite Health Benefits. <i>Journal of Urology</i> , 2012, 188, 1942-1943.	0.4	0
458	Re: Diagnosing and Treating Testosterone Deficiency in Different Parts of the World: Changes Between 2006 and 2010. <i>Journal of Urology</i> , 2012, 188, 1875-1876.	0.4	0
459	Trends in Care Delivery for Disorders of the Female Pelvic Floor. <i>Current Bladder Dysfunction Reports</i> , 2012, 7, 194-200.	0.5	0
460	Re: Active Surveillance for Prostate Cancer Compared with Immediate Treatment: An Economic Analysis. <i>Journal of Urology</i> , 2013, 189, 2109-2110.	0.4	0
461	Capsule Commentary on Shahinian et al.: Patterns of Bone Mineral Density Testing in Men Receiving Androgen Deprivation for Prostate Cancer. <i>Journal of General Internal Medicine</i> , 2013, 28, 1494-1494.	2.6	0
462	Re: On Average, Physicians Spend Nearly 11 Percent of Their 40-Year Careers with an Open, Unresolved Malpractice Claim. <i>Journal of Urology</i> , 2013, 190, 1005-1005.	0.4	0
463	Re: Safety and Treatment Patterns of Angiogenesis Inhibitors in Patients with Metastatic Renal Cell Carcinoma: Evidence from US Community Oncology Clinics. <i>Journal of Urology</i> , 2013, 189, 842-842.	0.4	0
464	Re: Explaining Racial Differences in Prostate Cancer Mortality. <i>Journal of Urology</i> , 2013, 189, 2109-2109.	0.4	0
465	Re: Health Benefits in 2012: Moderate Premium Increases for Employer-Sponsored Plans; Young Adults Gained Coverage under ACA. <i>Journal of Urology</i> , 2013, 189, 1481-1481.	0.4	0
466	Re: Factors Influencing Treatment Decision Making and Information Preferences of Prostate Cancer Patients on Active Surveillance. <i>Journal of Urology</i> , 2013, 189, 530-531.	0.4	0
467	Re: Cost-Effectiveness Analysis of Degarelix for Advanced Hormone-Dependent Prostate Cancer. <i>Journal of Urology</i> , 2013, 189, 531-531.	0.4	0
468	Re: Effect of Nonpayment for Preventable Infections in U.S. Hospitals. <i>Journal of Urology</i> , 2013, 189, 1738-1739.	0.4	0

#	ARTICLE	IF	CITATIONS
469	Re: Decision Aids: When “Nudging”™ Patients to Make a Particular Choice is More Ethical than Balanced, Nondirective Content. Journal of Urology, 2013, 190, 1251-1251.	0.4	0
470	Editorial Comment. Journal of Urology, 2013, 190, 398-398.	0.4	0
471	Re: Nurse-Led Flexible Cystoscopy in Australia: Initial Experience and Early Results. Journal of Urology, 2013, 190, 977-978.	0.4	0
472	Re: Optimization of PSA Screening Policies: A Comparison of the Patient and Societal Perspectives. Journal of Urology, 2013, 189, 529-530.	0.4	0
473	Re: Primary Prevention of Nephrolithiasis is Cost-Effective for a National Healthcare System. Journal of Urology, 2013, 190, 902-902.	0.4	0
474	Re: Dropout in the Treatment of Erectile Dysfunction with PDE5: A Study on Predictors and a Qualitative Analysis of Reasons for Discontinuation. Journal of Urology, 2013, 190, 988-989.	0.4	0
475	Re: Insights from Transformations Under Way at Four Brookings-Dartmouth Accountable Care Organization Pilot Sites. Journal of Urology, 2013, 190, 218-219.	0.4	0
476	Re: Prostate Cancer Screening in Men Ages 75 and Older Fell by 8 Percentage Points after Task Force Recommendation. Journal of Urology, 2013, 190, 1250-1251.	0.4	0
477	Re: A Simulation Shows Limited Savings from Meeting Quality Targets under the Medicare Shared Savings Program. Journal of Urology, 2013, 189, 1481-1482.	0.4	0
478	Re: Long-Term Disease-Specific Functioning Among Prostate Cancer Survivors and Noncancer Controls in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Journal of Urology, 2013, 189, 902-902.	0.4	0
479	Re: The New Era of Payment Reform, Spending Targets, and Cost Containment in Massachusetts: Early Lessons for the Nation. Journal of Urology, 2013, 189, 1483-1483.	0.4	0
480	Re: Characteristics of Persons with Overactive Bladder of Presumed Neurologic Origin: Results from the Boston Area Community Health (BACH) Survey. Journal of Urology, 2013, 190, 977-977.	0.4	0
481	Re: Socioeconomic Status, Healthcare Density, and Risk of Prostate Cancer Among African American and Caucasian Men in a Large Prospective Study. Journal of Urology, 2013, 189, 2108-2108.	0.4	0
482	Re: Fee-for-Service Will Remain a Feature of Major Payment Reforms, Requiring More Changes in Medicare Physician Payment. Journal of Urology, 2013, 189, 1482-1483.	0.4	0
483	Re: National Health Spending in 2011: Overall Growth Remains Low, but Some Payers and Services Show Signs of Acceleration. Journal of Urology, 2013, 190, 1004-1005.	0.4	0
484	Re: Certificate of Need Regulations and the Diffusion of Intensity-Modulated Radiotherapy. Journal of Urology, 2013, 190, 1250-1251.	0.4	0
485	Re: A Survey Analysis Suggests that Electronic Health Records Will Yield Revenue Gains for Some Practices and Losses for Many. Journal of Urology, 2013, 190, 1004-1004.	0.4	0
486	Re: Prostate Specific Antigen Testing Policy Worldwide Varies Greatly and Seems Not to Be in Accordance with Guidelines: A Systematic Review. Journal of Urology, 2013, 190, 1766-1767.	0.4	0

#	ARTICLE	IF	CITATIONS
487	Re: Temporal National Trends of Minimally Invasive and Retropubic Radical Prostatectomy Outcomes from 2003 to 2007: Results from the 100% Medicare Sample. Journal of Urology, 2013, 189, 125-126.	0.4	0
488	Leapfrog Volume Thresholds and Perioperative Complications After Radical Prostatectomy. Journal of Urology, 2013, 189, 126-127.	0.4	0
489	Accountable Care Organizations in Surgery: Location, Location, Location. JAMA Surgery, 2013, 148, 554.	4.3	0
490	Editorial Comment. Urology, 2014, 84, 1328.	1.0	0
491	Response. Journal of the National Cancer Institute, 2014, 106, djt466-djt466.	6.3	0
492	Re: Views of US Physicians about Controlling Health Care Costs. Journal of Urology, 2014, 191, 761-762.	0.4	0
493	Re: Variation among Primary Care Physicians in Prostate-Specific Antigen Screening of Older Men. Journal of Urology, 2014, 191, 1291-1292.	0.4	0
494	Re: Medical Communication Companies and Industry Grants. Journal of Urology, 2014, 192, 191-191.	0.4	0
495	Re: The Anatomy of Health Care in the United States. Journal of Urology, 2014, 192, 190-191.	0.4	0
496	Re: For States that Opt out of Medicaid Expansion: 3.6 Million Fewer Insured and \$8.4 Billion Less in Federal Payments. Journal of Urology, 2014, 191, 436-437.	0.4	0
497	Learning to see the forest through the trees. Surgery, 2014, 155, 797-798.	1.9	0
498	Re: Value-Based Insurance Design: Quality Improvement but No Cost Savings. Journal of Urology, 2014, 191, 761-762.	0.4	0
499	Re: Surgical Site Infections Following Ambulatory Surgery Procedures. Journal of Urology, 2014, 192, 431-432.	0.4	0
500	Re: States with the Least Restrictive Regulations Experienced the Largest Increase in Patients Seen by Nurse Practitioners. Journal of Urology, 2014, 191, 1363-1364.	0.4	0
501	Re: Specialty, Political Affiliation, and Perceived Social Responsibility are Associated with U.S. Physician Reactions to Health Care Reform Legislation. Journal of Urology, 2014, 191, 437-438.	0.4	0
502	Re: Surgery versus Physiotherapy for Stress Urinary Incontinence. Journal of Urology, 2014, 191, 423-423.	0.4	0
503	Re: Introduction of Surgical Safety Checklists in Ontario, Canada. Journal of Urology, 2014, 192, 1146-1147.	0.4	0
504	The Impact of Gender on Use of Pelvic Lymphadenectomy at the Time of Radical Cystectomy. Urology Practice, 2014, 1, 146-150.	0.5	0

#	ARTICLE	IF	CITATIONS
505	Re: Physicians'™ Attitudes about Multiplex Tumor Genomic Testing. Journal of Urology, 2014, 192, 1422-1423.	0.4	0
506	Re: National Health Spending in 2012: Rate of Health Spending Growth Remained Low for the Fourth Consecutive Year. Journal of Urology, 2014, 192, 899-900.	0.4	0
507	Re: Survey Finds Few Orthopedic Surgeons Know the Costs of the Devices they Implant. Journal of Urology, 2014, 192, 899-900.	0.4	0
508	Re: Effectiveness of Primary Androgen-Deprivation Therapy for Clinically Localized Prostate Cancer. Journal of Urology, 2014, 192, 1422-1422.	0.4	0
509	Re: National Trends in Patient Safety for Four Common Conditions, 2005-2011. Journal of Urology, 2014, 192, 1147-1147.	0.4	0
510	Re: Public Financing of the Medicare Program Will Make its Uniform Structure Increasingly Costly to Sustain. Journal of Urology, 2014, 191, 436-437.	0.4	0
511	Re: Massachusetts General Physicians Organization's Quality Incentive Program Produces Encouraging Results. Journal of Urology, 2014, 192, 189-190.	0.4	0
512	Re: Comparative Effectiveness of Skin Antiseptic Agents in Reducing Surgical Site Infections: A Report from the Washington State Surgical Care and Outcomes Assessment Program. Journal of Urology, 2014, 192, 431-432.	0.4	0
513	Re: The Quality of Care Delivered to Patients within the Same Hospital Varies by Insurance Type. Journal of Urology, 2014, 192, 190-190.	0.4	0
514	Re: Surgical Skill and Complication Rates after Bariatric Surgery. Journal of Urology, 2014, 191, 437-438.	0.4	0
515	Re: Screening for Prostate Cancer with the Prostate-Specific Antigen Test: A Review of Current Evidence. Journal of Urology, 2014, 192, 422-423.	0.4	0
516	Re: Variation in Treatment Recommendations of Adjuvant Radiation Therapy for High-Risk Prostate Cancer by Physician Specialty. Journal of Urology, 2014, 191, 658-658.	0.4	0
517	Re: Despite Overall Improvement in Surgical Outcomes since 2000, Income-Related Disparities Persist. Journal of Urology, 2014, 192, 191-191.	0.4	0
518	Re: Use of Statins and the Risk of Death in Patients with Prostate Cancer. Journal of Urology, 2014, 191, 1288-1289.	0.4	0
519	Editorial Comment. Journal of Urology, 2014, 192, 719-719.	0.4	0
520	Re: Bisphosphonate Prescriptions in Men with Androgen Deprivation Therapy Use. Journal of Urology, 2015, 194, 116-117.	0.4	0
521	Re: Hospital Closures had No Measurable Impact on Local Hospitalization Rates or Mortality Rates, 2003-11. Journal of Urology, 2015, 194, 1386-1387.	0.4	0
522	Re: Association of Hospital Participation in a Quality Reporting Program with Surgical Outcomes and Expenditures for Medicare Beneficiaries. Journal of Urology, 2015, 194, 1068-1070.	0.4	0

#	ARTICLE	IF	CITATIONS
523	Re: Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma. Journal of Urology, 2015, 194, 1710-1711.	0.4	0
524	Editorial Comment. Urology, 2015, 86, 1112-1113.	1.0	0
525	Re: Changes in Health Care Spending and Quality 4 Years into Global Payment. Journal of Urology, 2015, 193, 2056-2057.	0.4	0
526	Re: Association between Hospital Conversions to For-Profit Status and Clinical and Economic Outcomes. Journal of Urology, 2015, 193, 2056-2057.	0.4	0
527	Re: Association of the 2011 ACGME Resident Duty Hour Reform with General Surgery Patient Outcomes and with Resident Examination Performance. Journal of Urology, 2015, 193, 1616-1617.	0.4	0
528	Re: Making Cuts to Medicare: The Views of Patients, Physicians, and the Public. Journal of Urology, 2015, 194, 502-502.	0.4	0
529	Re: Association between Cannabis Use and the Risk of Bladder Cancer: Results from the California Men's Health Study. Journal of Urology, 2015, 194, 667-667.	0.4	0
530	Re: The Affordable Care Act Reduces Emergency Department Use by Young Adults: Evidence from Three States. Journal of Urology, 2015, 193, 952-953.	0.4	0
531	Re: Long-Term Effect of Hospital Pay for Performance on Mortality in England. Journal of Urology, 2015, 193, 953-954.	0.4	0
532	Re: Health Care Coverage under the Affordable Care Act—A Progress Report. Journal of Urology, 2015, 193, 952-953.	0.4	0
533	Re: A Comparison of Hospital Administrative Costs in Eight Nations: US Costs Exceed All Others by Far. Journal of Urology, 2015, 193, 953-954.	0.4	0
534	Re: Ultrasonography versus Computed Tomography for Suspected Nephrolithiasis. Journal of Urology, 2015, 193, 899-899.	0.4	0
535	Re: Vasectomy and Risk of Aggressive Prostate Cancer: A 24-Year Follow-up Study. Journal of Urology, 2015, 193, 628-629.	0.4	0
536	Re: Health Spending Slowdown is Mostly Due to Economic Factors, Not Structural Change in the Health Care Sector. Journal of Urology, 2015, 193, 1615-1616.	0.4	0
537	Re: Patient-to-Physician Messaging: Volume Nearly Tripled as More Patients Joined System, but Per Capita Rate Plateaued. Journal of Urology, 2015, 193, 1616-1617.	0.4	0
538	Re: National Health Expenditure Projections, 2013-23: Faster Growth Expected with Expanded Coverage and Improving Economy. Journal of Urology, 2015, 194, 501-502.	0.4	0
539	Re: Disparities in Stage at Diagnosis, Treatment, and Survival in Nonelderly Adult Patients with Cancer According to Insurance Status. Journal of Urology, 2015, 194, 501-502.	0.4	0
540	Re: Robot-Assisted Surgery for Kidney Cancer Increased Access to a Procedure that can Reduce Mortality and Renal Failure. Journal of Urology, 2015, 194, 333-333.	0.4	0

#	ARTICLE	IF	CITATIONS
541	Re: Risk of Fracture after Radical Cystectomy and Urinary Diversion for Bladder Cancer. Journal of Urology, 2015, 193, 1518-1518.	0.4	0
542	Adherence to Therapy for Lower Urinary Tract Symptoms: Donâ€™t Mistake Association with Causation!. European Urology, 2015, 68, 426-427.	1.9	0
543	Re: Physician Practice Competition and Prices Paid by Private Insurers for Office Visits. Journal of Urology, 2015, 193, 2057-2057.	0.4	0
544	Re: Exploring the Burden of Inpatient Readmissions after Major Cancer Surgery. Journal of Urology, 2015, 194, 1068-1068.	0.4	0
545	Re: Concentration in Orthopedic Markets was Associated with a 7 Percent Increase in Physician Fees for Total Knee Replacements. Journal of Urology, 2015, 194, 1386-1387.	0.4	0
546	Re: Lower Urinary Tract Symptoms and Risk of Bladder Cancer in Men: Results from the Health Professionals Follow-up Study. Journal of Urology, 2015, 194, 1231-1232.	0.4	0
547	Re: An Early Look at Changes in Employer-Sponsored Insurance under the Affordable Care Act. Journal of Urology, 2015, 194, 1069-1070.	0.4	0
548	Re: Attention to Surgeons and Surgical Care is Largely Missing from Early Medicare Accountable Care Organizations. Journal of Urology, 2015, 193, 257-257.	0.4	0
549	Re: Vertical Integration: Hospital Ownership of Physician Practices is Associated with Higher Prices and Spending. Journal of Urology, 2015, 193, 256-257.	0.4	0
550	Re: Measuring Low-Value Care in Medicare. Journal of Urology, 2015, 193, 258-258.	0.4	0
551	Re: First National Survey of ACOs Finds that Physicians are Playing Strong Leadership and Ownership Roles. Journal of Urology, 2015, 193, 258-259.	0.4	0
552	Re: Procedures Take Less Time at Ambulatory Surgery Centers, Keeping Costs Down and Ability to Meet Demand Up. Journal of Urology, 2015, 193, 257-259.	0.4	0
553	Re: National Prostate Cancer Screening Rates after the 2012 US Preventive Services Task Force Recommendation Discouraging Prostate-Specific Antigen-Based Screening. Journal of Urology, 2016, 195, 928-929.	0.4	0
554	Re: Less Physician Practice Competition is Associated with Higher Prices Paid for Common Procedures. Journal of Urology, 2016, 195, 1078-1079.	0.4	0
555	Re: Efficiency, Satisfaction, and Costs for Remote Video Visits following Radical Prostatectomy: A Randomized Controlled Trial. Journal of Urology, 2016, 195, 928-929.	0.4	0
556	Re: Trends in Health Insurance Enrollment, 2013-15. Journal of Urology, 2016, 195, 457-457.	0.4	0
557	Re: Emergency Department Revisits for Patients with Kidney Stones in California. Journal of Urology, 2016, 196, 138-138.	0.4	0
558	Re: The Correlation of Media Rankingâ€™s â€œBestâ€•Hospitals and Surgical Outcomes following Radical Cystectomy for Urothelial Cancer. Journal of Urology, 2016, 196, 353-354.	0.4	0

#	ARTICLE	IF	CITATIONS
559	Re: Mortality, Hospitalizations, and Expenditures for the Medicare Population Aged 65 Years or Older, 1999-2013. Journal of Urology, 2016, 195, 1078-1079.	0.4	0
560	Re: Kentucky's Medicaid Expansion Showing Early Promise on Coverage and Access to Care. Journal of Urology, 2016, 196, 1234-1235.	0.4	0
561	Re: Long Term Safety of Sacral Nerve Modulation in Medicare Beneficiaries. Journal of Urology, 2016, 196, 1504-1504.	0.4	0
562	Re: Economic Analysis of Prostate-Specific Antigen Screening and Selective Treatment Strategies. Journal of Urology, 2016, 196, 1127-1128.	0.4	0
563	Re: Androgen Deprivation Therapy and Future Alzheimer's Disease Risk. Journal of Urology, 2016, 196, 1126-1127.	0.4	0
564	Editorial Comment. Journal of Urology, 2016, 196, 740-740.	0.4	0
565	Re: US Physician Practices Spend More than \$15.4 Billion Annually to Report Quality Measures. Journal of Urology, 2016, 196, 1233-1234.	0.4	0
566	Re: Real-World Patterns of Care for the Overactive Bladder Syndrome in the United States. Journal of Urology, 2016, 196, 848-848.	0.4	0
567	"Killing two birds with one stone": patient-reported quality of life outcomes from the Prostate Testing for Cancer and Treatment (ProtecT) trial. BJU International, 2016, 118, 844-845.	2.5	0
568	Re: Oncologic Surveillance after Surgical Resection for Renal Cell Carcinoma: A Novel Risk-Based Approach. Journal of Urology, 2016, 195, 1720-1720.	0.4	0
569	Re: Outcomes of Daytime Procedures Performed by Attending Surgeons after Night Work. Journal of Urology, 2016, 195, 458-458.	0.4	0
570	Re: Cancer Mortality Reductions were Greatest among Countries where Cancer Care Spending Rose the Most, 1995-2007. Journal of Urology, 2016, 195, 456-457.	0.4	0
571	Re: Program Directors' Criteria for Selection into Urology Residency. Journal of Urology, 2016, 195, 457-457.	0.4	0
572	Re: Tracking Trends in Provider Reimbursements and Patient Obligations. Journal of Urology, 2016, 195, 1567-1567.	0.4	0
573	Re: Trends in Prostate-Specific Antigen Screening, Prostate Biopsies, Urology Visits, and Prostate Cancer Treatments from 2000 to 2012. Journal of Urology, 2016, 195, 1473-1474.	0.4	0
574	Re: Access to Care and Affordability have Improved following Affordable Care Act Implementation; Problems Remain. Journal of Urology, 2016, 195, 1866-1867.	0.4	0
575	Re: Profiling Individual Surgeon Performance Using Information from a High-Quality Clinical Registry: Opportunities and Limitations. Journal of Urology, 2016, 195, 1866-1867.	0.4	0
576	Re: Association of Pioneer Accountable Care Organizations vs Traditional Medicare Fee for Service with Spending, Utilization, and Patient Experience. Journal of Urology, 2016, 195, 456-457.	0.4	0

#	ARTICLE	IF	CITATIONS
577	Re: Early Impact of Medicare Accountable Care Organizations on Cancer Surgery Outcomes. Journal of Urology, 2017, 197, 241-242.	0.4	0
578	Re: Urologist Participation in Medicare Shared Savings Program Accountable Care Organizations (ACOs). Journal of Urology, 2017, 197, 241-242.	0.4	0
579	Re: Urologist-Level Correlation in the Use of Observation for Low- and High-Risk Prostate Cancer. Journal of Urology, 2017, 197, 401-402.	0.4	0
580	Re: The Effects of Oncologist Implicit Racial Bias in Racially Discordant Oncology Interactions. Journal of Urology, 2017, 197, 788-789.	0.4	0
581	Re: Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. Journal of Urology, 2017, 197, 702-704.	0.4	0
582	Re: Active Surveillance of Prostate Cancer in a Community Practice: How to Measure, Manage, and Improve?. Journal of Urology, 2017, 197, 703-703.	0.4	0
583	Re: Association of Androgen Deprivation Therapy with Depression in Localized Prostate Cancer. Journal of Urology, 2017, 197, 703-704.	0.4	0
584	Re: Liking Health Reform but Turned Off by Toxic Politics. Journal of Urology, 2017, 197, 242-242.	0.4	0
585	Re: Vasectomy and Prostate Cancer Incidence and Mortality in a Large US Cohort. Journal of Urology, 2017, 198, 104-106.	0.4	0
586	Re: Increase in Prostate Cancer Distant Metastases at Diagnosis in the United States. Journal of Urology, 2017, 198, 104-105.	0.4	0
587	Re: Effect of Home Monitoring via Mobile App on the Number of In-Person Visits following Ambulatory Surgery: A Randomized Clinical Trial. Journal of Urology, 2017, 198, 473-475.	0.4	0
588	Re: Changes in Health Status and Care Use after ACA Expansions among the Insured and Uninsured. Journal of Urology, 2017, 197, 1337-1338.	0.4	0
589	Re: Projecting the Urology Workforce over the Next 20 Years. Journal of Urology, 2017, 197, 1339-1339.	0.4	0
590	Re: Assessment of Overall Survival, Quality of Life, and Safety Benefits Associated with New Cancer Medicines. Journal of Urology, 2017, 197, 1220-1221.	0.4	0
591	Re: Gaining Coverage in 2014: New Estimates of Marketplace and Medicaid Transitions. Journal of Urology, 2017, 197, 1545-1546.	0.4	0
592	Re: Marketplace Plans with Narrow Physician Networks Feature Lower Monthly Premiums than Plans with Larger Networks. Journal of Urology, 2017, 197, 1546-1546.	0.4	0
593	Re: Uncompensated Care Decreased at Hospitals in Medicaid Expansion States but Not at Hospitals in Nonexpansion States. Journal of Urology, 2017, 197, 1337-1338.	0.4	0
594	Re: Better Patient Care at High-Quality Hospitals May Save Medicare Money and Bolster Episode-Based Payment Models. Journal of Urology, 2017, 197, 1338-1339.	0.4	0

#	ARTICLE	IF	CITATIONS
595	Re: Financial Relationships with Industry among National Comprehensive Cancer Network Guideline Authors. Journal of Urology, 2017, 197, 788-789.	0.4	0
596	Re: Sharp Decline in Prostate Cancer Treatment among Men in the General Population, but Not among Diagnosed Men. Journal of Urology, 2017, 198, 734-735.	0.4	0
597	Re: Low-Volume vs High-Volume Centers and Management of Fournier's Gangrene in Washington State. Journal of Urology, 2017, 198, 248-248.	0.4	0
598	Re: Identifying Drivers of Episode Cost Variation with Radical Prostatectomy. Journal of Urology, 2017, 198, 105-106.	0.4	0
599	Re: Preoperative Frailty Predicts Postoperative Complications and Mortality in Urology Patients. Journal of Urology, 2017, 198, 474-474.	0.4	0
600	Re: Short-Form Charlson Comorbidity Index for Assessment of Perioperative Mortality after Radical Cystectomy. Journal of Urology, 2017, 198, 474-475.	0.4	0
601	Re: Association between Radiation Therapy, Surgery, or Observation for Localized Prostate Cancer and Patient-Reported Outcomes after 3 Years. Journal of Urology, 2017, 198, 744-745.	0.4	0
602	Re: Public Perceptions of Overlapping Surgery. Journal of Urology, 2017, 198, 971-972.	0.4	0
603	Re: Types and Distribution of Payments from Industry to Physicians in 2015. Journal of Urology, 2017, 198, 971-972.	0.4	0
604	Re: Changes in Hospital Quality Associated with Hospital Value-Based Purchasing. Journal of Urology, 2017, 198, 972-972.	0.4	0
605	Re: High Volume is the Key for Improving In-Hospital Outcomes after Radical Prostatectomy: A Total Population Analysis in Germany from 2006 to 2013. Journal of Urology, 2017, 198, 1199-1201.	0.4	0
606	Re: Treatment Decision Regret among Long-Term Survivors of Localized Prostate Cancer: Results from the Prostate Cancer Outcomes Study. Journal of Urology, 2017, 198, 1200-1200.	0.4	0
607	Re: National Health Spending: Faster Growth in 2015 as Coverage Expands and Utilization Increases. Journal of Urology, 2017, 198, 247-247.	0.4	0
608	Re: At Federally Funded Health Centers, Medicaid Expansion was Associated with Improved Quality of Care. Journal of Urology, 2017, 198, 246-247.	0.4	0
609	Re: A Comparison of Web-Based versus Print-Based Decision Aids for Prostate Cancer Screening: Participants' Evaluation and Utilization. Journal of Urology, 2017, 197, 154-154.	0.4	0
610	Re: Treatment Preferences for Active Surveillance versus Active Treatment among Men with Low-Risk Prostate Cancer. Journal of Urology, 2017, 197, 153-154.	0.4	0
611	Reply to I.E. Haines. Journal of Clinical Oncology, 2017, 35, 1626-1627.	1.6	0
612	Validating the total illness burden index for prostate cancer (TIBI-CaP) in men with castration-resistant prostate cancer: data from TRUMPET. Future Oncology, 2018, 14, 527-536.	2.4	0

#	ARTICLE	IF	CITATIONS
613	Re: Narrow Networks on the Health Insurance Marketplaces: Prevalence, Pricing, and the Cost of Network Breadth. Journal of Urology, 2018, 199, 883-884.	0.4	0
614	Re: Strategies for Identifying and Closing the Gender Salary Gap in Surgery. Journal of Urology, 2018, 199, 332-334.	0.4	0
615	Re: Medicare's Acute Care Episode Demonstration: Effects of Bundled Payments on Costs and Quality of Surgical Care. Journal of Urology, 2018, 199, 333-334.	0.4	0
616	Re: Sustained Gains in Coverage, Access, and Affordability under the ACA: A 2017 Update. Journal of Urology, 2018, 199, 883-885.	0.4	0
617	Editorial Comment. Journal of Urology, 2018, 199, 1232-1232.	0.4	0
618	Re: Testosterone Replacement Therapy and Risk of Favorable and Aggressive Prostate Cancer. Journal of Urology, 2018, 199, 19-20.	0.4	0
619	Re: Electronic Health Record Logs Indicate that Physicians Split Time Evenly between Seeing Patients and Desktop Medicine. Journal of Urology, 2018, 199, 20-20.	0.4	0
620	Multiparametric magnetic resonance imaging (<scp>MRI</scp>) with targeted fusion biopsy: is the time now?. BJU International, 2018, 122, 1-2.	2.5	0
621	Reply to Potential underestimation of cerebrovascular events in the PROVENGE Registry for the Observation, Collection, and Evaluation of Experience Data. Cancer, 2020, 126, 2935-2937.	4.1	0
622	Editorial Comment. Journal of Urology, 2021, 205, 1646-1646.	0.4	0
623	Association between pelvic nodal radiotherapy and patient-reported functional outcomes through 5 years among men undergoing external-beam radiotherapy for prostate cancer: An assessment of the comparative effectiveness analysis of surgery and radiation (CEASAR) cohort. Urologic Oncology: Seminars and Original Investigations, 2021, 40, 56.e1-56.e1.	1.6	0
624	Quality-of-Life Issues in Incontinence. , 2004, , 53-64.		0
625	Changing trends in pelvic lymphadenectomy in radical prostatectomy with the advent of robotic surgery.. Journal of Clinical Oncology, 2013, 31, 39-39.	1.6	0
626	Bone health among prostate cancer survivors: Long-term follow-up from the Prostate Cancer Outcomes Study (PCOS).. Journal of Clinical Oncology, 2013, 31, 106-106.	1.6	0
627	Sensitivity of Medicare claims to identify recurrence.. Journal of Clinical Oncology, 2013, 31, 6522-6522.	1.6	0
628	Introduction of a tobacco-screening initiative for those at risk for bladder cancer in a high volume urology clinic.. Journal of Clinical Oncology, 2013, 31, 4540-4540.	1.6	0
629	Influence of age on incident diabetes (DM) and cardiovascular disease (CVD) among prostate cancer survivors receiving androgen deprivation therapy (ADT).. Journal of Clinical Oncology, 2014, 32, 31-31.	1.6	0
630	Influence of age on incident diabetes (DM) and cardiovascular disease (CVD) among prostate cancer survivors receiving androgen deprivation therapy (ADT).. Journal of Clinical Oncology, 2014, 32, 6583-6583.	1.6	0

#	ARTICLE	IF	CITATIONS
631	Time to chemotherapy following treatment with sipuleucel-T: Data from PROCEED.. Journal of Clinical Oncology, 2014, 32, 5040-5040.	1.6	0
632	Bisphosphonate utilization among men with metastatic castration-resistant prostate cancer (CRPC).. Journal of Clinical Oncology, 2015, 33, e16088-e16088.	1.6	0
633	Changing characteristics of patients treated with sipuleucel-T (sip-T) over time: Real-world experience from the PROCEED registry.. Journal of Clinical Oncology, 2016, 34, 320-320.	1.6	0
634	The TRUMPET registry: Assessing clinical outcomes and quality of life in patients with castration-resistant prostate cancer and their caregivers.. Journal of Clinical Oncology, 2016, 34, 241-241.	1.6	0
635	Treatment patterns for metastatic castration-resistant prostate cancer (mCRPC) in oncology (ONC) urology (URO) practices: Data from the PROCEED registry.. Journal of Clinical Oncology, 2016, 34, e16503-e16503.	1.6	0
636	Relationship between smoking, prognostic factors, and outcomes in patient (pts) with metastatic castration-resistant prostate cancer (mCRPC) receiving sipuleucel-T (sip-T): Preliminary analysis of the PROCEED registry.. Journal of Clinical Oncology, 2017, 35, 216-216.	1.6	0
637	The association of BMI and PSA density on survival among patients with metastatic or castration-resistant prostate cancer.. Journal of Clinical Oncology, 2017, 35, 207-207.	1.6	0
638	Validation of the total illness burden index for prostate cancer (TIBI-CaP) in men with castration-resistant prostate cancer (CRPC): Data from TRUMPET.. Journal of Clinical Oncology, 2017, 35, 256-256.	1.6	0
639	Comparison of enzalutamide and bicalutamide in patients with non-metastatic castration-resistant prostate cancer: Number needed to treat to achieve one additional patient free of clinical progression events.. Journal of Clinical Oncology, 2018, 36, 228-228.	1.6	0
640	Impact of enzalutamide (ENZA) vs. bicalutamide (BIC) on health-related quality of life (HRQoL) of patients (pts) with castration-resistant prostate cancer (CRPC): STRIVE study.. Journal of Clinical Oncology, 2018, 36, 234-234.	1.6	0
641	Do accountable care organizations affect race mediated differences in cancer screening?. Journal of Clinical Oncology, 2018, 36, 131-131.	1.6	0
642	Sipuleucel-T (sip-T) overall survival (OS) and clinical outcomes by baseline (BL) prostate-specific antigen (PSA) quartiles in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): PROCEED registry.. Journal of Clinical Oncology, 2018, 36, 5041-5041.	1.6	0
643	Influence of facility (Fac) annual caseload (AC) on survival of patients (pts) with respectable urothelial carcinoma (UC) of the bladder.. Journal of Clinical Oncology, 2018, 36, e16513-e16513.	1.6	0
644	Clinical events associated with cumulative corticosteroid use in patients with castration-resistant prostate cancer: An administrative claims analysis.. Journal of Clinical Oncology, 2019, 37, 236-236.	1.6	0
645	Cognitive effects of androgen receptor (AR) directed therapies for advanced cancer of the prostate (COGCaP).. Journal of Clinical Oncology, 2019, 37, TPS5098-TPS5098.	1.6	0
646	Editorial Comment. Journal of Urology, 2019, 202, 972-972.	0.4	0
647	A Modest Proposal: Prostate Biopsies and In-house Pathology Laboratories. Reviews in Urology, 2013, 15, 135-6.	0.9	0
648	Association between adherence to radiation therapy quality metrics and patient reported outcomes in prostate cancer. Prostate Cancer and Prostatic Diseases, 2022, , .	3.9	0

#	ARTICLE	IF	CITATIONS
649	Mathematical Issues: PSA Testing. , 0, , 47-62.		0
650	Impact of PSMA-targeted PET/CT in the clinical management of men with advanced prostate cancer.. Journal of Clinical Oncology, 2022, 40, e17053-e17053.	1.6	0